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Abstract 
The nonapeptide, oxytocin (OT), is implicated in a range of behavioural and 
physiological functions. However, OT’s role in sickness behaviours remains unclear. 
This thesis examined effects of the OT agonist, carbetocin (CBT), and OT antagonist, L-
368,899, on anxiety and locomotor sickness-related behaviours and pro-inflammatory 
cytokines, TNF- and IL-6, in adult male CD-1 mice. Animals received 2 intraperitoneal 
treatment injections. The first treatment was carbetocin, L-368,899, or saline, while the 
second was lipopolysaccharide (LPS) or saline. Behaviours were evaluated via the light-
dark test, and cytokines via immunoassay. OT antagonist treatment attenuated LPS 
induced perturbations in locomotor and anxiety-like behaviour, but produced no 
significant effects on cytokines. The 10mg/kg CBT-saline treatment suppressed 
locomotion, and augmented anxiogenic behaviour, while OT antagonist treatment 
augmented locomotor behaviour, and decreased anxiety-like behaviour. The present 
findings suggest that OT antagonist treatment has anxiolytic effects on basal anxiety-like 
behaviours, and attenuates the expression of sickness behaviour. 
 
 
 
Keywords: oxytocin, agonist, carbetocin, antagonist, L-368,899, lipopolysaccharide, 
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GENERAL INTRODUCTION 
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1.1. General Introduction 
The nonapeptide, oxytocin (OT), has been implicated in a broad range of 
behavioural and physiological functions. For example, evidence from humans and non-
human animals demonstrates that OT mediates various pro-social behaviours such as 
maternal nurturing, mother-infant bonding, pair-bonding, and alloparental care (Ross & 
Young, 2009). In humans, OT has also been shown to enhance interpersonal trust, 
affiliation, and sensitivity to inferring the emotions of others (Feldman et al., 2016; Ross 
& Young, 2009). There is, however, also evidence indicating that OT plays a role in other 
types of behaviour, including “antisocial” behaviour characterized by avoidance, 
aggression, and reduced social contact (Alcorn et al., 2015; Beery, 2015), as well as 
immune-related behaviours such as the recognition and mediation of avoidance response 
to infection and pathogen threat (Arakawa et al., 2015; Choleris et al., 2009; Kavaliers & 
Choleris, 2011). Such findings from previous studies are consistent with the idea that OT 
is involved in the mediation of responses to socially salient information, and that OT can 
either augment or attenuate social behaviour according to the social context (Feldman et 
al., 2016; Guzman et al., 2014; Guzman et al., 2013; Shamay-Tsoory & Abu-Akel, 2016). 
As previous studies have demonstrated, OT is associated with behavioural responses 
related to the detection of sickness and infection (eg. Arakawa et al., 2015). However, 
whether OT is also associated with the expression of sickness behaviours remains 
unclear.  
1.1.1. Oxytocin, Stress, and Anxiety  
OT is synthesized in 2 major sites within the hypothalamus: the paraventricular 
nucleus (PVN) and the supraoptic nucleus (SON); two areas which are also associated 
with hypothalamic-pituitary-adrenal (HPA) axis function (Insel, 1992; Love, 2014; 
Neumann & Landgraf, 2012; Ross & Young, 2009). After synthesis, OT is released into 
circulation via axonal projections from the posterior pituitary via the neurohypophyseal 
system (Insel, 1992; Neumann & Landgraf, 2012; Ross & Young, 2009). High densities 
of OT and its receptors are found in limbic regions including the nucleus accumbens, 
central amygdala, ventromedial hypothalamus, and as well as the hypothalamic 
endocannabinoid system (Choleris et al., 2013; De Laurentiis et al., 2010; Peters et al., 
2014; Tops et al., 2004). These are neural regions which have been associated with 
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stress-related behaviours (eg. increased anxiety) and physiological cascades, as well as 
immune function (Duval et al., 2015; Viveros et al., 2005). Moreover, OT receptor 
expression is also influenced by genetic variation, age, sex, and early environmental 
experiences such as exposure to stress or trauma (Bakos et al., 2014; Buisman-Pijlman et 
al., 2014).  
Increasing evidence suggests that OT plays an important role in modulating the 
stress response and potentially immune function as well (Wang et al., 2015). Importantly, 
there is substantial evidence that OT can have suppressive effects on the HPA-axis, 
helping to reduce circulating levels of cortisol/corticosterone and adrenocorticotropic 
hormone (ACTH) (Clodi et al., 2008; Brunton et al., 2012; Detillion et al., 2004; DeVries 
et al., 2007; Landgraf et al., 1995; Neumann et al., 2000). This impact of OT on the HPA-
axis may mediate effects on immune function, decreasing pro-inflammatory cytokine 
activation (Wang et al., 2015). For example, in hamsters, treatment with OT or housing 
conditions allowing for social interaction led to reduced HPA-axis and pro-inflammatory 
cytokine activation, thus promoting more rapid wound healing (DeVries et al., 2007). 
Conversely, it was shown that hamsters who received treatment with an OT antagonist or 
who were individually housed displayed increased HPA-axis and pro-inflammatory 
cytokine activation, and inhibited wound healing (Detillion et al., 2004; DeVries et al., 
2007; Neumann et al., 2000). Taken together, evidence from these studies clearly 
indicates a role for OT in mediating HPA-axis as well as immunological functions.  
Accumulating evidence suggests that systemic levels of OT may also influence 
other behaviours associated with HPA activation, including locomotor and anxiety-like 
behaviour. Importantly, treatment with an OT agonist has been shown to reduce anxiety-
like behaviour in a variety of animal models (Harari-Dahan & Bernstein, 2014; 
Neumann, 2008; Neumann & Slattery, 2015; Peters et al., 2014). Positive social 
interaction and social bonding experiences, such as being socially housed, mating, and 
parental care have been shown to increase endogenous levels of OT, and may also buffer 
against the deleterious effects of anxiety, and attenuate anxiety-like behaviour in rodents 
via OT mediated mechanisms (DeVries et al., 2007; Neumann, 2008; Tops et al., 2014). 
Conversely, studies have shown that when rodents receive treatment with an OT 
antagonist or are housed individually, anxiety-like behaviour increases (Neumann & 
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Slattery, 2015; Ring et al., 2006). However, there is also a small but growing body of 
data suggesting that OT may either have no effect, or may augment anxiety responses, 
which appears to be very much context and situation specific (Guzman et al., 2014; 
Guzman et al., 2013; Shamay-Tsoory & Abu-Akel, 2016).  
Although augmented levels of OT tend to induce anxiolytic effects, and 
attenuated OT levels have been associated with increased anxiety, conflicting data 
suggests that these effects may be dose- and context-related (Guzman et al., 2014; Peters 
et al., 2014; Ring et al., 2006). For example, Ring et al. (2006) found dose-related effects 
of OT on anxiety-like behaviours in male mice as indexed by the four-plate test. Here, 
systemic OT (3.0 – 30 mg/kg i.p.) treatment resulted in anxiolytic effects on behaviour; 
the 10 mg/kg dose of OT produced the greatest number of increased punished crossings, 
indicating both dose-related, and anxiolytic effects of peripheral OT (Ring et al., 2006). 
Similarly, Peters et al. (2014) chronically administered high (10 ng/h) or low (1 ng/h) 
doses of OT intracerebroventricularly (ICV), and found that the high dose of OT 
increased anxiogenic behaviour as indexed by reduced time spent in the light chamber of 
the Light-Dark test, and less time spent in the open arms of an elevated plus maze (EPM), 
while the low dose of OT increased locomotor activity (Peters et al., 2014). Conversely, 
Guzman et al. (2014) showed that in male mice, ICV treatment to the lateral septum with 
an OT antagonist abolished social fear conditioning. Their results indicated a 
bidirectional role for OT in fear conditioning as OT led to decreased fear after positive, 
but increased fear after negative social encounters (Guzman et al., 2014). Evidently, the 
putative dose- and context-related nature of OT effects on anxiety-like behaviour remains 
poorly understood.     
1.1.2. Oxytocin, Immune Function, and CD38 
Results of studies examining CD38, a type II transmembrane glycoprotein, further 
support the link between OT, immune function, and behaviour. In humans and other 
animals CD38 plays a role in immune, social behaviour, and OT mediated functions 
(Algoe & Way, 2014; Feldman et al., 2016; Higashida et al., 2012; Jin et al., 2007; Lerer 
et al., 2010). For example, Partida-Sanchez et al. (2001) showed that trafficking of 
neutrophils to inflammatory and infected sites was dependent upon CD38 expression on 
neutrophils, providing evidence of a role for CD38 in immune function and inflammatory 
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mechanisms. Results of investigations with mice have also shown that CD38 regulates in 
vivo functions of immune-related cells, such as dendritic cells, monocytes, and 
neutrophils (Lund, 2006). Furthermore, Lerer et al. (2010) found that lymphocytes from 
Autism Spectrum Disorder (ASD) patients had significantly less CD38 expression, 
compared to the patients’ unaffected parents. As patients diagnosed with ASD display 
hallmark dysfunction of social behaviour including the OT-related behaviours of social 
cognition, social approach, and affiliative behaviour (Lukas & Neumann, 2013), these 
data provide support for the integrated role of CD38 and OT in immune function and 
social behaviour. 
1.1.3. Oxytocin, LPS, and Sickness Behaviour 
 Lipopolysaccharide (LPS) is an endotoxin from the outer cell wall of Gram-
negative bacteria, which activates both immune and endocrine systems including the 
HPA-axis (Anisman & Merali, 2002; Anisman et al., 2003; Clodi et al., 2008; Ross et al., 
2013). In both humans and non-human animals, LPS has reliably and consistently been 
shown to induce robust immune responses and sickness behaviours (Anisman & Merali, 
2002). Sickness behaviours refer to a complex suite of coordinated behaviours that occur 
after the onset of infection, and are elicited by pro-inflammatory cytokines in both 
humans and other animals (Anisman et al., 2003; Aubert, 1999; Dantzer & Kelley, 2007; 
Kelley et al., 2003; Shattuck & Muehlenbein, 2015; York at el., 2012). Specific 
behaviours indicative of sickness include lethargy, anorexia, depression, cognitive 
changes, decreased sex drive, anhedonia, sleep disturbance, hyperalgesia, and social 
withdrawal and isolation (Kelley et al., 2003; Shattuck & Muehlenbein, 2015). For 
example, Banasikowski et al. (2015) showed dose- and context-related effects of LPS 
treatment on locomotor and anxiety-like behaviour in the light-dark test in male mice. 
LPS at 25g/kg (i.p.), but not 1g/kg or 5g/kg, significantly enhanced anxiety-like 
behaviour on the first day of testing (Banasikowski et al., 2015). Similarly, Engeland et 
al. (2001) also found context-related effects on locomotor behaviour following LPS 
treatment as animals displayed significant reductions in locomotor activity, and 
environmental novelty was shown to mediate the locomotor reducing effects of LPS in 
male mice. Furthermore, in adult male rats, Reyes-Lagos et al. (2016) showed that LPS at 
0.1mg/kg (i.p.) significantly increased mean heart rate and body temperature, and 
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attenuated locomotor behaviour in freely moving animals, indicating LPS-induced 
endotoxemia. These and other studies provide evidence for the role of LPS in affecting 
sickness behaviours, including anxiety, and immune responses.  
Cytokines communicate with the central nervous system via the endocrine route 
or by direct neural transmission via the vagus nerve, alerting the brain that an infection 
has occurred (Anisman & Merali, 2002; Dantzer & Kelley, 2007; Kelley et al., 2003). 
Cytokines that are synthesized and released during the early stages of response to 
infection, and which have been strongly and consistently associated with sickness 
behaviour include interleukin 1 beta (IL-1), interleukin 6 (IL-6), and tumor necrosis 
factor alpha (TNF-) (Anisman & Merali, 2002; Anisman et al., 2003; Kelley at al., 
2003; Shattuck & Muehlenbein, 2015).  
OT has been shown to affect serum and brain levels of IL-1, IL-6, and TNF- 
levels (Wang et al., 2013). Results of studies have shown that pro-inflammatory 
cytokines, such as TNF- and IL-1, stimulate release of both OT and AVP both in vitro 
and in vivo (Anisman et al., 2003; Landgraf et al., 1995; Shattuck & Muehlenbein, 2015). 
For instance, Landgraf et al. (1995) found that central administration of IL-1 induced 
the release of OT and AVP within the supraoptic nucleus in rats. Moreover, LPS 
treatment, which stimulates the production of pro-inflammatory cytokines including 
TNF-, similarly appears to cause increases in plasma OT (De Laurentiis et al., 2010). 
These studies further underscore the link between OT and immune function. There is, 
however, limited research on the effects of OT as it relates specifically to the expression 
of sickness behaviour. For example, only a recent study by Reyes-Lagos et al. (2016) 
investigated OT’s role in mediating heart rate fluctuations, body temperature, and 
locomotor activity (ie. sickness behaviour) in adult male rats challenged with LPS. They 
found that in animals administered LPS plus OT, there was a decrease in mean heart rate, 
and OT appeared to moderate LPS-induced hyperthermia, while also increasing 
locomotor activity for up to 6 hours post LPS treatment (Reyes-Lagos et al., 2016), 
providing evidence that OT does influence these particular sickness behaviours. Based on 
previous limited research, it is clear that OT does play a role in mediating HPA-related 
physiological and behavioural mechanisms, immune function, and potentially sickness 
behaviour. However, more research is needed to clarify OT’s role regarding specific 
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sickness behaviours, such as locomotor activity and anxiety-like behaviour, in the context 
of LPS-induced immune activation.  
1.1.4. Present Study 
 Results of previous studies have produced mixed results regarding the effects of 
OT on both locomotor and anxiety-like behaviour, immune function, and that expressed 
during sickness following LPS treatment. In this study the effects of the OT agonist, 
carbetocin, and OT antagonist, L-368,899, on sickness and anxiety-like behaviour 
induced by LPS administration were examined, along with levels of pro-inflammatory 
cytokines TNF- and IL-6. Locomotor and anxiety-like sickness-related behaviours were 
evaluated in the light-dark test, as the automated apparatus allows for examination of 
both anxiety and locomotor behavioural parameters (Arrant et al., 2013; Banasikowski et 
al., 2015; Bourin & Hascoet, 2003). Cytokine parameters were measured from trunk 
blood collection following LPS treatment and behavioural testing.  
In the study of locomotor and anxiety-like behaviours affected by sickness, it was 
hypothesized that animals receiving treatment with the OT agonist, carbetocin (Engstrøm 
et al., 1998; Moertl et al., 2011), in combination with LPS would demonstrate attenuated 
anxiety responses and normalized locomotor activity. It was also hypothesized that 
animals treated with the OT antagonist, L-368,899 (Kuteykin-Teplyakov & Maldonado 
2014; Olszewski et al., 2015; Olszewski et al., 2014), would show augmented anxiety-
like behaviour and reduced locomotor activity. In the second study, which examined 
OT’s role in pro-inflammatory responses, it was hypothesized that the OT agonist would 
result in reduced serum levels of pro-inflammatory cytokines TNF- and IL-6, elicited by 
LPS treatment, while the OT antagonist was predicted to elevate these cytokine levels.  
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2.1 Introduction 
There is accumulating evidence suggesting that the nonapeptide, oxytocin (OT), is 
involved in mediating various social behaviours. However, OT also appears to play a role 
in affecting behavioural and physiological mechanisms that underlie the experience and 
expression of stress and anxiety (Choleris et al., 2013; DeVries et al., 2007; Guzman et 
al., 2013; Neumann & Landgraf, 2012; Neumann & Slattery, 2015). “Sickness 
behaviours”, which refer to a complex suite of coordinated behaviours that occur after the 
onset of infection, consist of numerous behavioural symptoms including anxiety, as well 
as lethargy, and social withdrawal and isolation, among others (Anisman et al., 2003; 
Aubert, 1999; Dantzer & Kelley, 2007; Kelley et al., 2003; Shattuck & Muehlenbein, 
2015; York at el., 2012). Given the putative link between OT, stress, and anxiety 
(Neumann & Landgraf, 2012; Neumann & Slattery, 2015) and the relation between 
sickness behaviours and anxiety, it is plausible that OT may also participate in the 
regulation and expression of sickness behaviours. This is a topic which has received 
relatively minimal attention to date, and remains largely unclear.  
2.1.1. Oxytocin, LPS, and Sickness Behaviour 
Lipopolysaccharide (LPS) is an endotoxin from the outer cell wall of Gram-
negative bacteria, which activates both immune and endocrine systems including the 
HPA-axis (Anisman & Merali, 2002; Anisman et al., 2003; Clodi et al., 2008; Ross et al., 
2013). In both humans and non-human animals, previous studies have shown that LPS 
reliably and consistently induces robust immune responses and sickness behaviours 
(Anisman & Merali, 2002). For instance, Banasikowski et al. (2015) showed dose- and 
context-related effects of LPS treatment on locomotor and anxiety-like behaviour in the 
light-dark test in male mice. LPS at 25g/kg (i.p.), but not 1g/kg or 5g/kg, 
significantly enhanced anxiety-like behaviour on the first day of testing (Banasikowski et 
al., 2015). Likewise, Reyes-Lagos et al. (2016) showed that LPS at 0.1mg/kg (i.p.) 
significantly increased mean heart rate and body temperature, and attenuated locomotor 
behaviour in freely moving adult male rats, indicating LPS-induced sickness via cytokine 
mediated mechanisms.  
Cytokines communicate with the central nervous system via the endocrine route 
or by direct neural transmission via the vagus nerve, alerting the brain that infection has 
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occurred in the periphery (Anisman & Merali, 2002; Dantzer & Kelley, 2007; Kelley et 
al., 2003). Cytokines, including interleukin 1 beta (IL-1), interleukin 6 (IL-6), and tumor 
necrosis factor alpha (TNF-), are synthesized and released during the early stages of an 
acute phase response to infection and have consistently been associated with sickness 
behaviour (Anisman & Merali, 2002; Anisman et al., 2003; Dantzer & Kelly, 2007; 
Kelley at al., 2003; Shattuck & Muehlenbein, 2015). OT has been linked to alterations in 
IL-1, IL-6, and TNF- levels during the sickness response (Wang et al., 2013), and pro-
inflammatory cytokines, such as TNF- and IL-1 have been shown to stimulate the 
release of both OT and AVP (Anisman et al., 2003; Landgraf et al., 1995; Shattuck & 
Muehlenbein, 2015).  
Sickness behaviours refer to a constellation of coordinated behaviours that occur 
after the onset of infection, and are elicited by pro-inflammatory cytokines in both 
humans and non-human animals (Anisman et al., 2003; Aubert, 1999; Dantzer & Kelley, 
2007; Kelley et al., 2003; Shattuck & Muehlenbein, 2015; York at el., 2012). Specific 
behaviours indicative of sickness include lethargy, depression, anxiety, anorexia, 
cognitive changes, decreased sex drive, anhedonia, sleep disturbance, hyperalgesia, and 
social withdrawal and isolation (Kelley et al., 2003; Shattuck & Muehlenbein, 2015). 
Sickness behaviours are an adaptive response to illness and infection, and motivate an 
organism in reorganize its priorities so as to promote recovery and survival (Aubert, 
1999; Dantzer & Kelley, 2007; Shattuck & Muehlenbein, 2015). Previous findings 
illustrate a link between OT and immune function. However, research on the effects of 
OT specifically relating to sickness behaviours is quite sparse, thus the current study 
provides a novel examination of OT’s role in specific sickness behaviours following an 
immune challenge. 
2.1.2. Oxytocin and Anxiety 
 Studies have demonstrated that systemic levels of OT appear to influence 
behaviour associated with HPA activity, such as anxiety behaviour, as well as that related 
to immune activation-induced sickness behaviour (eg. locomotor activity). Previous 
studies have found both systemic and central treatment with various OT agonists and 
antagonists to be efficacious in examining OT’s effects on anxiety behaviours. For 
instance, treatment with an OT agonist was shown to reduce anxiety-like behaviour in a 
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variety of rodent species, such as rats and mice, using a battery of anxiety-specific 
behavioural assays, including the light-dark test, elevated plus maze, four plate test, and 
open field test (Harari-Dahan & Bernstein, 2014; Neumann, 2008; Neumann & Slattery, 
2015; Peters et al., 2014; Ring et al., 2006; York et al., 2012). Similarly, social bonding 
experiences such as being socially housed, mating, and parental care seem to buffer 
against the deleterious effects of anxiety (eg. immune suppression, adrenal fatigue, 
aberrant social behaviour, etc.), and attenuate anxiety-like behaviour presumably via OT 
mediated mechanisms (DeVries et al., 2007; Neumann, 2008; Tops et al., 2014). For 
example, in female Siberian hamsters treatment with OT, or housing conditions allowing 
for social interaction with a same-sex sibling, led to reduced activity within the HPA-
axis, and pro-inflammatory cytokine activation, promoting more rapid wound healing 
(DeVries et al., 2007).  Conversely, studies have shown that when animals receive OT 
antagonist treatment or are housed in isolation, anxiety-like behaviour (Neumann & 
Slattery, 2015; Ring et al., 2006), HPA activity, and pro-inflammatory cytokines 
increase, and wound healing is inhibited (Detillion et al., 2004; DeVries et al., 2007; 
Neumann et al., 2000). 
Previous studies show inconsistent findings with respect to dose-related effects of 
OT on behavioural and physiological parameters. For example, to evaluate OT’s putative 
dose-related effects on anxiety- and stress-related parameters in male mice, Peters et al. 
(2014) chronically administered high (10 ng/h) or low (1 ng/h) doses of OT 
intracerebroventricularly (ICV). High dose OT resulted in increased anxiogenic 
behaviour indexed by reduced time spent in the light chamber of the Light-Dark (LD) 
test, and less time spent in the open arms of an elevated plus maze (EPM), while low 
dose OT animals displayed increased locomotor activity in the LD test (Peters et al., 
2014). Similarly, Ring et al. (2006) found dose-related effects of OT and the OT 
antagonist, WAY-162720, on anxiety-like behaviours in male mice as indexed by the 
four-plate test (FPT). Findings showed that systemic OT (3.0 – 30 mg/kg i.p.) treatment 
30 minutes prior to testing resulted in anxiolytic effects on behaviour. Importantly, the 10 
mg/kg dose of OT produced the greatest number of increased punished crossings, 
indicating both a dose-related, and anxiolytic effects of peripheral OT. Treatment with 
the OT antagonist, WAY-162720, reversed the anxiolytic effects of OT (Ring et al., 
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2006). In evaluating the effects of 3 doses (2 mg/kg, 6.4 mg/kg, or 20 mg/kg. i.p.) of the 
OT agonist, carbetocin, on open field behaviour in male rats, Chaviaras et al. (2010) 
found that only the 20 mg/kg dose led to a significant decrease in the total distances 
animals travelled, providing further evidence of dose related effects of OT treatment on 
behaviour.  
Within human research, results have also been variable regarding OT’s role in 
anxiety. Consistent with much animal research, Scantamburlo et al. (2007) found that 
endogenous OT appears to have anxiolytic effects, as patients with major depression with 
higher plasma levels of OT show attenuated anxiety. Others have reported that in 
individuals with depressive symptoms, lower levels of OT tend to be associated with 
augmented anxiety levels (Harari-Dahan & Bernstein, 2014). OT may be related to 
depressive symptoms, and the often comorbid syndrome of anxiety, through the 
inflammatory hypothesis of depression. This hypothesis states that symptoms of 
depression, including depressive and anxiety behaviour, may result from augmented 
levels of pro-inflammatory cytokine activity (ie. inflammation) (Maes, 2011). 
Although augmented levels of OT tend to induce anxiolytic effects, and 
attenuated OT levels are associated with increases in anxiety, other data suggests that 
these effects may be context dependent (Peters et al., 2014). Furthermore, there are a 
small but growing number of studies suggesting that OT may either have no effect, or 
cause a slight augmentation of anxiety responses following OT receptor activation 
(Choleris et al., 2007). For example, Donhoffner et al. (2016) showed that in female adult 
rats central (ICV) OT treatment had no effect on either locomotor or anxiety-like 
behaviour in the elevated plus maze. Inconsistent findings highlight the critical role of 
contextual cue salience within OT mediated behavioural responses, and whether such 
cues are social or non-social in nature (Choleris et al., 2013; Shamay-Tsoory & Abu-
Akel, 2016). The present study provides necessary additional examination of the putative 
dose-related and context-dependent nature of OT’s effects on anxiety-like behaviour 
within animal models. 
2.1.3. Present Study 
 This study evaluated the effects of the OT agonist, carbetocin, and OT antagonist, 
L-368,899, on the expression of locomotor and anxiety-like sickness-related behaviours 
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affected by LPS treatment. Locomotor and anxiety-like behaviours were indexed via an 
automated light-dark test. This apparatus allowed for examination of both anxiety-like 
and locomotor behaviours simultaneously (Arrant et al., 2013; Banasikowski et al., 2015; 
Bourin & Hascoet, 2003). Importantly, this study provided a novel investigation into 
OT’s role in the expression of specific sickness behaviours, along with anxiety-like 
behaviour.  
Based on previous research, it was hypothesized that OT agonist treatment would 
attenuate the expression of sickness responses, thereby suppressing locomotor activity 
and anxiety-like behaviour among animals treated with the OT agonist in conjunction 
with LPS. That is, animals treated with the OT agonist plus LPS were expected to exhibit 
normal levels (ie. similar to that of controls) of locomotor activity, and to spend less time 
in the dark chamber of the LD test. Furthermore, animals treated with the OT agonist plus 
saline were hypothesized to show increased locomotor activity and anxiolytic behaviour. 
Conversely, animals treated with the OT antagonist, L-368,899, in combination with LPS 
were hypothesized to show reduced locomotor activity and augmented anxiety-like 
behaviour. 
2.2 Methods 
2.2.1. Animals 
A total of 91 adult male CD-1 mice (30 to 35 grams) from Charles River, Quebec, 
were used. Animals were housed in a temperature controlled colony room at 211°C, 
with photoperiod set to a 12:12 Light:Dark cycle with lights on at 0700, and were 
provided food (ProLab rodent chow, RMH 3000) and water ad libitum. Animals were 
housed individually in polypropylene cages (29.5 x 18.8 x 13 cm). Effects of individual 
housing on male mice are strain and density dependent, with previous studies indicating 
negligible differences in CD-1 mice with regard to basal stress responses between 
individually and socially housed males (Bartolomucci et al., 2003; Bartolomucci, 2007). 
However, individual housing was used in our study to prevent effects of inter-male 
aggression and minimize dominance-subordinance related differences in individual stress 
and OT responses, as social contextual variables have been shown to affect these 
(Choleris et al., 2013; DeVries et al., 2007). Mice were left undisturbed for 10 days prior 
to testing to ensure adequate adjustment time after arrival.  All procedures were approved 
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by the Western University Animal Care Committee and animals were handled and tested 
according to guidelines set out by the Canadian Council on Animal Care (CCAC).    
2.2.2. Drug Treatment 
Mice were randomly divided into 8 groups. Beginning between 12:00 and 13:00h, 
all animals received a series of 2 intraperitoneal (i.p.) injections, 15 minutes apart. Table 
2.1 outlines the group treatments and group sizes. The first injection manipulated OT 
levels. Here, 2 groups received a 20mg/kg dose of OT agonist, carbetocin (CBT) 
(Carbetocin acetate SML0748, no. 073M4722V, Sigma-Aldrich, St. Louis, MO, USA) 
dissolved in 0.9% isotonic saline, while 2 other groups received a 10mg/kg dose. Two 
different groups received a 10mg/kg dose of the OT antagonist, L-368,899 (L-368,899 
hydrochloride, no. 1A/82628, Tocris Bioscience, Minneapolis, MN, USA) dissolved in 
0.9% isotonic saline for their first injection, while the remaining 2 groups were 
administered a control injection of an equivalent volume of isotonic saline (0.9%). CBT 
was chosen as the OT agonist for its relatively long half-life (85 – 100 mins) (Engstrøm 
et al., 1998; Moertl et al., 2011) and the doses were based on behaviourally active doses 
previously reported in mice (eg. Chaviaras et al., 2010). Similarly, results from previous 
studies have shown L-368,899, at varying dosages, to be an effective OT antagonist in 
mice with the dose used here being based on these studies (Kuteykin-Teplyakov & 
Maldonado 2014; Olszewski et al., 2015; Olszewski et al., 2014). 
The second injection 15 mins later initiated an immune challenge. Animals 
received either g/kg Lipopolysaccharide (LPS) (derived from Escherichia Coli 
serotype 0111:B4, no. L2630-028K4090, Sigma Chemical, St. Louis, MO, USA) 
dissolved in a 0.9% isotonic saline, or saline as a control. This dose was selected based 
on the results of previous studies with CD-1 mice (Engeland et al., 2001).  
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Table 2.1. Group sizes and treatment injections for OT and LPS 
Group n Injection 1 Injection 2 
20CBT-LPS 12 20 mg/kg carbetocin g/kg LPS 
10CBT-LPS 12 10 mg/kg carbetocin g/kg LPS 
20CBT-NaCl 12 20 mg/kg carbetocin 0.2 to 0.35 mL saline 
10CBT-NaCl 12 10 mg/kg carbetocin 0.2 to 0.35 mL saline 
OTant-NaCl 7 10 mg/kg L-368,899 0.2 to 0.35 mL saline 
OTant-LPS 7 10 mg/kg L-368,899 g/kg LPS 
NaCl-LPS 15 0.2 to 0.35 mL saline g/kg LPS 
NaCl-NaCl 14 0.2 to 0.35 mL saline 0.2 to 0.35 mL saline 
 
2.2.3. Apparatus 
The Light-Dark (LD) apparatus consisted of 8 Plexiglas VersaMax Animal 
Activity Monitors (40 cm x 40 cm x 30.5 cm) (Accuscan Model RXYZCM-16, 
Columbus, OH), divided into two chambers. Infrared sensor beams were located every 
2.54 cm along the perimeter (16 along each side) and 2.5 cm above the floor. 
Additionally, 2 sets of 16 infrared beams were located 8.0 cm above the floor on opposite 
sides. Beam breaks generate measures of the animals' activity. Black Plexiglas boxes (40 
cm x 20cm x 30 cm) with small holes in the sides to avoid obstructing the infrared beams 
were inserted into each Activity Monitor. Thus the open-field was divided into two equal 
sized “dark” and “light” chambers. Animals had unrestricted access to both chambers via 
a 13.0 x 5 cm doorway. Clear Plexiglas lids with air-holes were used to prevent escape. 
Three fluorescent lights were located above the activity boxes providing a light source of 
approximately 900 lux at the floor of each light chamber.  Data were collected and 
analyzed by a VersaMax Analyzer (Accuscan Model CDA-8, Columbus, OH), which 
sent information to an IBM computer where it was recorded for future statistical analysis. 
2.2.4. Procedure 
Animals were habituated to the VersaMax LD test apparatus for 15 minutes on 
the day before drug administration and testing. On test day, animals received an injection 
of either CBT, L-368,899, or saline, followed 15 minutes later by an injection of either 
saline or LPS, and were then left undisturbed for 2 hours. This time frame was selected as 
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other studies have found that effects of the acute-phase sickness response, including 
autonomic, endocrine and behavioural events, appear to peak at approximately 2 hours 
following LPS administration (e.g. Engeland et al., 2001). Mice were gently placed into 
the light chamber of the apparatus after this 2 hour period and left undisturbed during 
testing. Data were collected for 15 minutes in the LD apparatus, as activity tends to 
markedly decline after 15 minutes (Bourin & Hascoet, 2003; Engeland et al., 2001).   
The LD test allows for the collection of data on both locomotor and anxiety 
parameters (Arrant et al., 2013; Bourin & Hascoet, 2003). For each chamber, measures of 
locomotor activity and anxiety-like behaviour were obtained and then corrected for 
unequal amounts of time spent in the chambers by dividing the given variable by the 
duration of time spent in the corresponding light or dark chamber. Horizontal movement 
variables included Total Distance travelled (total distance travelled in cm in each 
chamber), Speed (distance in centimeters travelled per second) and Movement Time 
(amount of time animals spent moving in the horizontal plane per second). Vertical 
activity variables included the time animals spent Rearing (time moving vertically per 
second), and the Number of Rears (number of times animals made vertical movements 
per second). Measures of anxiety-like behaviour included the Duration of time spent in 
seconds in the light chamber, the number of Nose Pokes into the light chamber (single 
beam breaks through the doorway between chambers), and the number of Transitions into 
the light chamber (full body crossed the center line).  
2.2.5. Data Analysis 
The effects of the OT agonist, CBT, OT antagonist, L-368,899, and LPS on 
locomotor activity and anxiety-like behaviours were evaluated using a multivariate 
Analysis of Variance (MANOVA) with between subjects factors of OT (4 levels: 
20mg/kg CBT, 10mg/kg CBT, 10mg/kg OT antagonist, saline (control)) and LPS (2 
levels: g/kg and saline (control). Post hoc pairwise comparisons were then completed 
where appropriate using the Least Significant Difference (LSD) to evaluate significant 
main effects and interactions. Behavioural data were analyzed using SPSS 23.0 for 
windows with  = 0.05, and the Greenhouse-Geisser correction factor where appropriate. 
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2.3 Results 
2.3.1. Effects of LPS on Locomotor Behaviour 
 In the dark chamber LPS treatment induced robust attenuations in both horizontal 
and vertical locomotor behaviour for all locomotor measures including Total Distances 
travelled, Speed, horizontal Movement Time, Time Rearing, and the Number of Rearing 
Movements, indicating sickness behaviour. In the light chamber LPS treatment 
suppressed locomotor behaviour for Total Distances travelled, Time Rearing, and the 
Number of Rearing Movements, demonstrating the occurrence of sickness behaviour in a 
context-dependent manner. 
Total Distance travelled in the dark and light chambers is shown in Figures 2.1: A 
– D. There was a significant main effect of LPS in both the dark [F(1, 85) = 74.68, p = 
.000] and the light chambers [F(1, 85) = 32.87, p = .000], with LPS treated animals 
travelling a significantly shorter distance in both chambers relative to non-LPS treated 
mice.  
Speed in the dark and light chambers is shown in Figure 2.2: A – D. A significant 
main effect of LPS in the dark chamber was found [F(1, 85) = 66.48, p = .000]. LPS 
treated animals travelled significantly slower than those treated with saline, suggesting 
that LPS treated animals experienced lethargy.  
Movement Time in the horizontal plane in both the dark and light chambers is 
shown in Figure 2.3: A – D. ANOVA analysis revealed a significant main effect of LPS 
treatment in the dark chamber [F(1, 85) = 34.76, p = .000].  LPS treated animals spent 
significantly less time moving in the horizontal plane relative to non-LPS treated animals, 
suggesting lethargy. 
Time Rearing in the dark and light chambers is shown in Figure 2.4: A – D. A 
significant main effect of LPS was observed in both the dark [F(1, 85) = 70.30, p = .000] 
and light [F(1, 85) = 55.86, p = .000] chambers. Here, LPS treated animals exhibited less 
rearing behaviour in both chambers relative to non-LPS treated mice, demonstrating LPS 
induced reductions in locomotor activity.  
The Number of Rearing Movements in the dark and light chambers is shown in 
Figure 2.5: A – D. ANOVA analysis revealed a significant main effect of LPS treatment 
for both the dark [F(1, 85) = 83.34, p = .000] and light [F(1, 85) = 22.58, p = .000] 
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chambers. LPS treated animals made significantly fewer rearing movements in both 
chambers relative to non-LPS treated groups, further reflecting an attenuation of 
locomotor activity following LPS treatment.  
2.3.2. OT Agonist and OT Antagonist Effects on Locomotor Behaviour 
In the dark chamber the OT agonist, CBT, was shown to affect locomotor 
behaviour in a dose-related manner for Speed, Time Rearing, and the Number of Rearing 
Movements. In particular, the 10mg/kg CBT-saline treated group tended to show reduced 
locomotor activity. OT antagonist treatment was also shown to affect locomotor 
behaviour in the dark chamber for Speed, Time Rearing, and the Number of Rearing 
Movements. OT antagonist-saline treated animals tended to show increased locomotor 
behaviour. Importantly, animals spent significantly more Time Rearing, and made a 
greater Number of Rearing Movements, than all other LPS groups, suggesting that OT 
antagonist treatment may attenuate aspects of sickness induced lethargy. 
In the light chamber the OT agonist, CBT, was shown to affect locomotor 
behaviour in a dose-related manner for the Total Distances animals’ travelled, such that 
10mg/kg CBT treated mice showed reductions in locomotor behaviour for this variable. 
However, no other significant main effects or interactions were found for locomotor 
behaviour in the light chamber, suggesting context-related effects of OT on locomotor 
behaviour.  
Total Distance travelled in the dark and light chambers is shown in Figures 2.1: A 
– D. There was a significant main effect of OT manipulation in the light chamber 
[F(3,85) = 3.43, p = .021]. Analysis of this main effect revealed  a dose-related effect of 
the OT agonist, CBT, with the 10mg/kg treated mice travelling a significantly shorter 
distance than the 20 mg/kg CBT treated group (p = .034) (Fig. 2.1 C). However, neither 
group differed significantly from the control group (p’s > .05). Main effects analysis also 
revealed a significant effect of the OT antagonist in the light chamber as these animals 
travelled significantly further compared to the 10 mg/kg CBT treated mice (p = .003) 
(Fig. 2.1 D). A significant LPS x OT interaction was not observed for Total Distances 
travelled in either the dark chamber [F(3, 85) = 2.51, p = .064] nor the light chamber 
[F(3, 85) = 2.16, p = .099]. 
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Speed in the dark and light chambers is shown in Figure 2.2: A – D. A significant 
main effect of OT manipulation on Speed was found in the dark chamber [F(3, 85) = 
3.89, p = .012]. Analysis of this main effect indicated that animals treated with the OT 
agonist, 10mg/kg CBT, travelled more slowly than those treated with 20mg/kg CBT (p = 
.029), but not saline controls (p = .119) (Fig. 2.2 A). Furthermore, effects of OT 
antagonist treatment were also found, where this group travelled significantly faster 
relative to the 10mg/kg CBT (p = .002) and saline control (p = .039) groups in the dark 
chamber (Fig. 2.2 B). A significant LPS x OT interaction was not found for either the 
dark chamber [F(3, 85) = 2.48, p = .066] nor the light chamber [F(3, 85) = .623, p = 
.602]. Furthermore, these locomotor activity effects on Speed were specific to the dark 
chamber as no significant main effects of OT or LPS, nor any significant interactions 
were found in the light chamber.  
Movement Time in the horizontal plane in both the dark and light chambers is 
shown in Figure 2.3: A – D. Significant main effects of OT were not observed. Moreover, 
a significant LPS x OT interaction was not found in either the dark [F(3, 85) = 1.56, p = 
.206] or light chambers [F( 3, 85) = .29, p = .833].  
Time Rearing in the dark and light chambers is shown in Figure 2.4: A – D. In the 
dark chamber, the ANOVA revealed a significant main effect of OT [F(3, 85) = 2.84, p = 
.043] on Time Rearing. Main effects analysis showed that mice treated with 10mg/kg 
CBT reared significantly less than animals treated with the OT antagonist (p = .006), but 
not saline controls (p = .073) (Fig. 2.4 A).  This effect was specific to the dark chamber 
as no significant differences were observed in the light chamber. In the dark chamber a 
significant LPS x OT interaction was found [F(3, 85) = 2.95, p = .038] for Time Rearing 
(Fig. 2.4 B). Post hoc analyses revealed dose related effects of CBT in the dark chamber 
as the 10mg/kg CBT-saline animals spent significantly less time rearing than the 
20mg/kg CBT-saline group (p = .014) and the saline-saline group (p = .017) . These data 
are again suggestive of suppressive effects of the 10mg/kg CBT dose on locomotor 
activity, though these effects appear to be context dependent as they were only observed 
in the dark chamber. Furthermore, OT antagonist-LPS treated animals spent significantly 
more time rearing than all other LPS groups (p’s < .011) providing evidence that OT 
antagonist treatment may attenuate aspects of sickness induced lethargy.  
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The Number of Rearing Movements in the dark and light chambers is shown in 
Figure 2.5: A – D. In the dark chamber, the main effect of OT manipulation approached 
significance [F(3, 85) = 2.65, p = .054]. This trend was again driven by dose-specific 
effects of OT agonist, where the 10mg/kg CBT treated group made fewer rearing 
movements compared to the OT antagonist group (p = .006), but not saline controls (p = 
.223) (Fig. 2.5 A). A significant main effect of OT manipulation in the light chamber was 
not observed. In the dark chamber a significant LPS x OT interaction was also found 
[F(3, 85) = 2.97, p = .036] on the Number of Rearing Movements animals made (Fig. 2.5 
B). Post hoc analyses indicated that dose-related effects of CBT treatment occurred as the 
10 mg/kg CBT-saline treated animals made significantly fewer rearing movements 
compared to the 20 mg/kg CBT-saline group (p = .024), though not saline controls (p = 
.084). This effect further highlights the dose-related effects of CBT treatment, and in 
particular that the 10 mg/kg CBT dose may have suppressive effects on locomotor 
behaviour. Furthermore, in the dark chamber the OT antagonist-LPS treated animals 
made significantly more rearing movements relative to all other LPS groups (p’s < .008), 
suggesting an attenuation of sickness induced lethargy. These effects appear to be 
context-dependent as effects of OT on locomotor behaviour only occurred in the dark 
chamber.  
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A       B 
  
C       D 
  
Fig. 2.1. (A – D) Mean Total Distance travelled in the dark (A – B) and the light (C – D) chamber 
during a 15 minute testing session for mice treated i.p. with an OT agonist (CBT), or OT 
antagonist, plus LPS or saline. Control groups are displayed twice for ease of data comparison. 
Vertical lines indicate standard error. LPS groups travelled significantly less in both light and 
dark chambers than non-LPS groups (p < .001; not marked on graph). In the light chamber, 10 
mg/kg CBT treatment significantly suppressed distances travelled relative to 20 mg/kg CBT (@ p 
= .034). OT antagonist treated mice in the light chamber travelled significantly further compared 
to the 10 mg/kg CBT treated mice (# p = .003).  
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A       B 
 
C       D 
 
Fig. 2.2. (A – D) Mean Speed in the dark (A – B) and light (C – D) chamber during a 15 minute 
testing session for mice treated i.p. with an OT agonist (CBT), or OT antagonist, plus LPS or 
saline. Control groups are displayed twice for ease of data comparison. Vertical lines indicate 
standard error. LPS treated groups moved significantly slower in the dark chamber relative to 
non-LPS treated animals (p < .001; not marked on graph). In the dark chamber, 10 mg/kg CBT 
treatment significantly attenuated Speed relative to 20mg/kg CBT (@ p’s = .029). OT antagonist 
treatment significantly augmented Speed in the dark chamber relative to 10 mg/kg CBT and 
saline controls (# p’s < .039).  
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A       B 
 
C       D 
 
Fig. 2.3. (A – D) Mean horizontal Movement Time in the dark (A – B) and the light (C – D) 
chamber during a 15 minute testing session for mice treated i.p. with an OT agonist (CBT), or OT 
antagonist, plus LPS or saline. Control groups are displayed twice for ease of data comparison. 
Vertical lines indicate standard error. In the dark chamber, LPS groups travelled significantly less 
in the horizontal plane compared to saline groups (p < .001; not marked on graph). 
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A       B 
 
 
C       D 
 
Fig. 2.4. (A – D) Mean Time Rearing in the dark (A – B) and light (C – D) chamber during a 15 
minute testing session for mice treated i.p. with an OT agonist (CBT), or OT antagonist, plus LPS 
or saline. Control groups are displayed twice for ease of data comparison. Vertical lines indicate 
standard error.  LPS groups spent significantly less time rearing in both chambers than non-LPS 
groups (p < .001; not marked on graph). In the dark chamber, OT antagonist-LPS mice reared 
significantly more relative to all other LPS groups (& p’s < .011). The 10 mg/kg CBT-saline mice 
spent significantly less time rearing than 20 mg/kg CBT-saline and saline-saline control groups 
(@ p’s < .017). 
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A       B 
 
 
C       D 
 
Fig. 2.5. (A – D) Mean Number of Rearing Movements in the dark (A – B) and light (C – D) 
chamber during a 15 minute testing session for mice treated i.p. with an OT agonist (CBT), or OT 
antagonist, plus LPS or saline. Control groups are displayed twice for ease of data comparison. 
Vertical lines indicate standard error. LPS groups spent significantly less time rearing in both 
chambers than non-LPS groups (p < .001; not marked on graph). In the dark chamber, OT 
antagonist-LPS treated mice made significantly more rearing movements compared to all other 
LPS treated groups (& p’s < .008) and 10 mg/kg CBT-saline mice spending significantly less 
time rearing relative to the 20 mg/kg CBT-saline group (@ p = .024). 
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2.3.3. Effects of LPS on Anxiety-like Behaviour 
In the light chamber LPS treatment increased anxiety-like behaviour as indicated 
by the reduced duration of Time animals spent in the light chamber, along with fewer 
Nose Pokes and Transitions into the light chamber, indicating sickness-induced anxiety-
like behaviour. 
Time in the light chamber is shown in Figure 2.6: A – B. Time in the dark 
chamber was not analyzed because the light-dark test was conducted in a forced-choice 2 
chamber apparatus and thus analysis would have yielded identical statistics to those 
stemming from the light chamber. ANOVA analysis revealed a significant main effect of 
LPS treatment [F(1, 85) = 21.71, p = .000], such that  LPS animals spent significantly 
less time in the light chamber (p < .001). This finding is indicative of the immune 
challenge augmenting anxiety-like behaviour as LPS animals spent less time in the light 
chamber relative to saline treated mice.  
Number of Nose Pokes into the light chamber is illustrated in Figure 2.7: A – B. 
The ANOVA revealed a significant main effect of LPS for Nose Pokes [F(1, 85) = 44.51, 
p = .000], whereby LPS treated animals made significantly fewer nose poke 
investigations into the light chamber, suggesting increased anxiety. 
The Number of Transitions into the light chamber is shown in figure 2.8: A – B. 
The ANOVA revealed a significant main effect of LPS treatment [F(1, 85) = 45.49, p = 
.000], as LPS groups made significantly fewer transitions into the light chamber than did 
saline groups (p’s < .001), indicative of enhanced anxiety.   
2.3.4. OT agonist and OT antagonist Effects on Anxiety-like Behaviour 
In the light chamber the OT agonist, CBT, was shown to affect anxiety-like 
behaviour for the Number of Nose Pokes and also Transitions into the light chamber in a 
dose-related manner. Specifically, mice treated with the 20mg/kg CBT dose made more 
Nose Pokes overall, and the 20mg/kg-saline, but not the 10mg/kg CBT-saline, treated 
mice made significantly more nose pokes into the light chamber. Furthermore, the 
10mg/kg CBT treated mice made fewer transitions into the light chamber overall. 
Effects on anxiety-like behaviour in the light chamber for the OT antagonist, L-
368,899, were also found for duration of Time spent in the light chamber, as well as for 
the Number of Nose Pokes and for Transitions into the light chamber. OT antagonist 
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treated mice spent more time in the light chamber relative to both OT agonist groups, and 
saline controls. As well, OT antagonist treated mice showed a greater number of Nose 
Pokes and Transitions into the light chamber, suggesting an attenuation of anxiety. 
Importantly, OT antagonist-LPS mice showed a greater number of Nose Pokes into the 
light chamber, demonstrating anxiolytic effects of the OT antagonist on sickness-induced 
anxiety-like behaviour.  
Time in the light chamber is shown in Figure 2.6: A – B. Time in the dark 
chamber was not analyzed because the light-dark test was conducted in a forced-choice 2 
chamber apparatus and thus analysis would have yielded identical statistics to those 
stemming from the light chamber. For duration of Time spent in the light chamber, a 
significant main effect of OT treatment was found [F(3, 85) = 4.21, p = .008]. Main 
effects analysis indicated that OT antagonist treated animals spent significantly more 
time in the light chamber relative to both the 10mg/kg (p = .001) and the 20mg/kg (p = 
.013) CBT treated groups, and saline control animals (p = .008) (Fig. 2.6 B). No 
significant LPS x OT interactions were observed [F(3, 85) = .414, p = .744]. 
Number of Nose Pokes into the light chamber is illustrated in Figure 2.7: A – B. 
The ANOVA revealed a significant main effect of OT on Number of Nose Pokes into the 
light chamber [F(3, 85) = 2.95, p = .037]. Animals treated with the 20mg/kg CBT dose or 
the OT antagonist made significantly more Nose Pokes into the light chamber compared 
to saline treated animals (p’s < .036) (Fig. 2.7: A – B). A significant LPS x OT 
interaction was also identified for Nose Pokes into the light chamber [F(3, 85) = 3.17, p 
=.028] (Fig. 2.7 B). Dose-related effects of CBT treatment were again observed as the 
20mg/kg-saline, but not the 10mg/kg CBT-saline, treated animals made significantly 
more nose pokes into the light chamber compared saline-saline controls (p = .002). 
Furthermore, post hoc analyses also revealed that the OT antagonist-LPS treated animals 
made significantly more nose pokes into the light chamber relative to all other LPS 
groups (p’s < .033). This provides additional evidence that OT antagonist treatment 
moderates the effect of LPS, here reducing LPS induced anxiety-like behaviour. 
The Number of Transitions into the light chamber is shown in figure 2.8: A – B. 
The ANOVA revealed a significant main effect of OT for transitions into the light 
chamber [F(3, 85) = 2.88, p = .041]. Analysis of main effects indicated that the 10mg/kg 
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CBT group made significantly fewer transitions into the light chamber compared to the 
OT antagonist group (p = .016), but not the 20 mg/kg group nor saline controls (Fig. 2.8: 
A – B). Furthermore, the OT antagonist animals transitioned more into the light chamber 
than saline controls (p = .031). A significant LPS x OT interaction was not observed for 
Transitions into the light chamber [F(3, 85) = 2.22, p = .091]. 
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  B 
 
Fig. 2.6. (A – B) Mean Time spent in the light chamber (A – B) during a 15 minute testing 
session for mice treated i.p. with an OT agonist (CBT), or OT antagonist, plus LPS or saline. 
Control groups are displayed twice for ease of data comparison. Vertical lines indicate standard 
error. LPS treated animals spent significantly less time in the light chamber relative to non-LPS 
treated groups of animals (p < .001; not marked on graph). OT antagonist treated mice spent 
significantly more time in the light chamber compared to CBT treated groups and the saline 
control group (# p’s < .013).  
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     A        
B  
 
Fig. 2.7 (A – B) Mean number of Nose Pokes into the light chamber (A – B) during a 15 minute 
testing session for mice treated i.p. with an OT agonist (CBT), or OT antagonist, plus LPS or 
saline. Control groups are displayed twice for ease of data comparison. Vertical lines indicate 
standard error. LPS treated animals spent significantly less time in the light chamber relative to 
non-LPS treated groups of animals (p < .001; not marked on graph). OT antagonist-LPS animals 
made significantly more nose pokes compared to all other LPS treated groups (& p’s < .033) and 
20mg/kg CBT-saline made significantly more nose pokes than saline-saline control animals (% p 
= .002). 
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Fig. 2.8 (A – B) Mean number of Transitions into the light chamber (A – B) during a 15 minute 
testing session for mice treated i.p. with an OT agonist (CBT), or OT antagonist, plus LPS or 
saline. Control groups are displayed twice for ease of data comparison. Vertical lines indicate 
standard error. LPS treated animals spent significantly less time in the light chamber relative to 
non-LPS treated groups of animals (p < .001; not marked on graph). 10 mg/kg CBT mice made 
significantly fewer transitions into the light chamber compared to OT antagonist treated mice (@ 
p = .016). OT antagonist animals made significantly more transitions into the light chamber 
relative to saline control animals (# p = .031). 
0
5
10
15
20
25
30
35
40
45
NaCl/LPS 10CBT/LPS 20CBT/LPS NaCl/NaCl 10CBT/NaCl 20CBT/NaCl
N
u
m
b
e
r 
o
f 
Tr
an
si
ti
o
n
s
OT Agonist Treatment
@
@
Light Chamber
0
5
10
15
20
25
30
35
40
45
NaCl/LPS OTant/LPS NaCl/NaCl OTant/NaCl
N
u
m
b
e
r 
o
f 
Tr
an
si
ti
o
n
s
OT Antagonist Treatment
#
#
Light Chamber
 
 
39 
 
2.4 Discussion 
To date few studies have examined the effects of OT on the expression of 
sickness behaviours, including locomotor and anxiety-like behaviour. Results of the 
present study demonstrate that treatment with the OT antagonist, L-368,899, in 
conjunction with 75 g/kg of LPS attenuates locomotor and anxiety-like sickness-related 
behaviours. Furthermore, dose-related effects of the OT agonist, carbetocin (CBT), on 
basal locomotor activity and anxiety-like behaviour were also shown. In particular, in 
conjunction with saline treatment the 10 mg/kg dose of CBT suppressed both horizontal 
and vertical locomotor behaviours, and augmented anxiety-like responses.  
2.4.1. Effects of OT on Sickness Behaviours 
Consistent with previous research (Engeland et al., 2001; Tenk et al., 2008), 
75g/kg of LPS treatment elicited a robust attenuation of both horizontal and vertical 
locomotor activity indicating sickness behaviour, as male CD-1 mice showed significant 
increases in lethargy in both chambers of the LD test. LPS treatment also significantly 
augmented anxiety-like behaviour in the light-dark test as demonstrated by significant 
reductions in the duration of time that animals spent in the light chamber, as well as 
fewer Nose Pokes and Transitions into the light chamber. This finding agrees with 
previous accounts of sickness-induced increases in anxiety-like behaviour characterized 
by an avoidance of brightly lit open spaces and more threatening contexts (Banasikowski 
et al., 2015; Bourin & Hascoet, 2003).  
The present study revealed that treatment with the OT antagonist, L-368,899, 
suppressed LPS-induced perturbations on locomotor and anxiety-like behavioural 
responses, while the OT agonist had no effect on sickness behaviour. Specifically, it was 
found that OT antagonist-LPS treated mice display increased time rearing, and an 
increased number of rearing movements in the dark chamber relative to all other LPS 
groups, illustrating the suppressive effect of the OT antagonist on LPS-induced lethargy. 
While this effect was not observed in the light chamber, previous research suggests that 
sickness behaviours are expressed in a context-dependent manner. In particular, sickness 
behaviours are more strongly expressed in the dark versus light chamber due to 
motivational reorganization since it is not adaptive for rodents to appear sick in 
threatening contexts, such as brightly lit open spaces (Arrant et al., 2013). As such, the 
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dark chamber may be a more accurate representation of the true level of sickness 
behaviour.  OT antagonist-LPS mice also showed attenuation of sickness-induced 
anxiety-like behaviour as these animals made significantly more Nose Poke 
investigations into the light chamber (ie. the more anxiogenic context) relative to all other 
LPS treated groups. As Figures 2.6 (B), 2.7 (B) and 2.8 (B) illustrate, OT antagonist-LPS 
treated mice behaved comparably to that of saline control mice for all anxiety measures. 
These findings are suggestive of OT antagonist treatment attenuating sickness behaviour 
by normalizing animals’ behaviour to levels similar to that of saline-control animals.  
There have been limited investigations of the effects of OT on the expression of 
sickness behaviours. However, Reyes-Lagos et al. (2016) did investigate OT’s role in 
mediating heart rate fluctuations, body temperature, and locomotor activity in adult male 
rats challenged with LPS. They found that in LPS treated animals OT decreased mean 
heart rate, moderated LPS-induced hyperthermia, and increased locomotor activity for up 
to 6 hours post LPS treatment (Reyes-Lagos et al., 2016). This finding is in contrast with 
that of the present study, which found that the OT agonist had no effect on sickness 
behaviours, while the OT antagonist suppressed sickness-induced locomotor and anxiety-
like behavioural perturbations.  
The difference in findings between the present study and that of Reyes-Lagos et 
al. (2016) could largely be due to methodological differences. Specifically, in their study 
locomotor activity was evaluated using telemetric electrocardiogram recording in freely 
moving rats in the home cage, whereas in the present study locomotor activity was 
evaluated in the more anxiogenic and stressful context of the light-dark test. Thus, in this 
study the more stressful context may have affected HPA-axis mediated OT mechanisms, 
causing differential effects on locomotor behaviour. Thus it is possible that the contextual 
differences between studies may, at least to some extent, account for the differential 
behavioural findings. Regardless, findings from the present study suggest that 
suppression of systemic OT may postpone the onset of sickness behaviour expression, or 
that it may block LPS induced pro-inflammatory mechanisms and suppress manifestation 
of sickness behaviours. However, the underlying physiological mechanisms responsible 
for these behavioural effects can only be speculated at this time. As such, more research 
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is needed to investigate OT’s apparent role in sickness behaviours, and elucidate 
underlying physiological mechanism that affect the expression of such behaviours.  
2.4.2. Effects of OT Agonist Treatment 
Treatment with the OT agonist, CBT, yielded dose-related effects on locomotor 
and anxiety-like behaviour. Specifically, the 10 mg/kg CBT treatment resulted in 
depressed locomotor activity in both the dark and light chamber as animals travelled 
shorter distances, more slowly, spent less time rearing, and made fewer rearing 
movements. This effect was not observed among the 20 mg/kg CBT or saline-control 
groups. These findings suggest that a dose of 10 mg/kg OT agonist suppressed locomotor 
activity in non-novel contexts. Interestingly, the 10 mg/kg CBT group demonstrated a 
reduced number of transitions into the light chamber relative to the 20 mg/kg CBT group, 
indicative of the 10 mg/kg CBT treatment augmenting anxiety-like responses and 
reducing exploratory behaviour in this context. In addition, the 20 mg/kg CBT treated 
animals made significantly more Nose Pokes into the light chamber relative to saline-
controls, suggestive of attenuated anxiety-like responses. 
Consistent with previous studies, the results of this study demonstrate dose-
related effects of OT on measures of anxiety in male rodents. For instance, Ring et al. 
(2006) observed dose related effects of OT as measured by the four-plate test (FPT) in 
adult male mice. However, in contrast with the present findings, Ring et al. (2006) found 
that administration of 10 mg/kg (i.p.) of OT 30 minutes prior to testing led to increased 
punished crossings, suggesting an anxiolytic effect of peripheral OT. Conversely, the 
present study showed that a dose of 10 mg/kg (i.p.) resulted in anxiogenic effects on 
behaviour. Chaviaras et al. (2010) found that in the open field test male rats treated with a 
high (ie. 20 mg/kg) but not low (ie. 2 mg/kg; 6.4 mg/kg) dose (i.p.) of OT agonist, 
carbetocin, 30 minutes prior to testing showed a significant decrease in total distances 
animals’ travelled, suggesting suppressed locomotor activity and increased anxiety. 
Again these findings are in contrast to those of the present study, as here it was found that 
the 20 mg/kg CBT (i.p.) dose resulted in anxiolytic effects on behaviour. 
The differences observed between the results of this and other studies could be 
attributed to the amount of time elapsed between OT administration and commencement 
of behavioural testing. In this study, behavioural testing did not occur until 2 hours after 
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OT agonist treatment, which is longer than the time elapsed between OT treatment and 
behavioural testing in other studies (Chaviaras et al., 2010; Ring et al., 2006). This 
differential finding may suggest that temporal variables play a role in mediating OT’s 
effects on anxiety-like behaviour, with OT exerting anxiolytic effects shortly after 
treatment, but having anxiogenic effects in a dose-related manner, following longer time 
delays between administration and testing. Importantly, another consideration for the 
present findings is that different anxiety tests will often produce different outcomes on 
behaviour. For instance, Hascoet et al. (2000) showed differential drug effects in a dose-
related manner between the light-dark and four plate tests in mice.  
Taken together, the results of this study in conjunction with previous research 
illustrate the dose-related and potentially temporally-dependent nature of anxiolytic and 
anxiogenic effects of OT on behaviour. Specifically, the present study confirms dose-
related effects of OT on behaviour as seen in previous studies. However, this study has 
also demonstrated that temporal and context-dependent effects exist. Compared to other 
studies that administered a 10mg/kg dose of OT but waited only 30 minutes between drug 
treatment and testing (Chaviaras et al., 2010; Ring et al., 2006), the 2 hour latency 
between OT administration and behavioural testing in the present study seemed to affect 
mice differently at this dose, increasing anxiety-like behaviour and suppressing 
locomotor activity. These findings also illustrate novel context-dependent effects of OT 
in relation to anxiety and locomotor behaviour, as previous studies examining OT have 
used other measures of anxiety, such as the elevated zero maze and four plate test (eg. 
Ring et al., 2006), finding differential effects on these behaviours compared to those of 
the current study.  
2.4.3. Effects of OT Antagonist Treatment 
Treatment with the OT antagonist, L-368-899, yielded intriguing results as 
animals showed increased locomotor activity in the dark chamber, travelled faster, and 
spent more time rearing relative to other groups. Furthermore, in the light chamber OT 
antagonist treated mice travelled a greater distance compared to other groups. These data 
suggest that a 10mg/kg (i.p.) dose of the OT antagonist may enhance locomotor and 
exploratory behaviour in male CD-1 mice. Behavioural anxiety indicators were also 
shown to be affected by treatment with the OT antagonist. In particular, OT antagonist 
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treated mice spent significantly more time in the light chamber, indicating anxiolytic-like 
behaviour. Furthermore, OT antagonist treated animals made significantly more Nose 
Pokes and Transitions into the light chamber, indicating an overall reduction in anxiety-
like behaviour.  
The present findings are in contrast with those of Ring et al. (2006) who found 
that the OT antagonist, WAY-162720, at 10 mg/kg (i.p.) 30 minutes prior to testing 
reversed the anxiolytic effects of OT in the four plate test, thereby demonstrating 
anxiogenic effects of peripheral OT antagonist treatment on behaviour. However, more 
recent studies have shown an effect consistent with that of the present study, as others 
have found that OT antagonist treatment has either no effect, or anxiolytic effects, in 
certain contexts. For example, Duque-Wilckens et al. (2016) showed that in female mice 
treated with L-368,899 (i.p.) 30 min before behavioural testing, the OT antagonist 
blocked the effects of stress in both the social interaction and odor preference tests, such 
that animals showed high levels of social interaction, and preferred the odor of an 
unfamiliar individual. Conversely, when stressed, saline treated mice showed reduced 
social interaction and a preference for the odor of a familiar cagemate, suggesting that 
OT antagonist treatment has anxiolytic effects on behaviour in social contexts (Duque-
Wilckens et al., 2016). Similarly, Arakawa et al. (2015) showed that in male mice OT 
antagonist treatment had limited effects on social approach behaviour, although it did 
significantly decrease the amount of social engagement time. These conflicting findings 
again demonstrate the role of context, temporal, and test-related effects of OT on 
behaviour (Hascoet et al., 2000; Ring et al., 2006).  
2.4.4. Limitations and Future Directions 
Methodological limitations within the present study may account for the results 
observed. In particular, calculating the dose of OT drugs to be used in mice was 
challenging as there are relatively few existing studies with which to determine dosages 
for mice. Furthermore, time-related factors, such as the 2 hour latency between OT 
treatment and behavioural testing, likely also influenced behavioural findings. As most 
studies conduct behavioural testing 30 minutes after OT treatment due to the relatively 
short half-life of OT (eg. Chaviaras et al., 2010; Ring et al., 2006), in the present study 
behavioural effects of OT may have been affected differently due to lower systemic 
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levels of OT, thus reducing its effects on behaviour. Future studies could examine OT’s 
effects on sickness and anxiety-like behaviour in mice at the same dosages used in this 
study, along with other doses, to elucidate dose-related effects of OT in mice. As well, 
examining OT’s effects on sickness and anxiety-like behaviours at different time points 
after drug administration may help to clarify time-related effects of OT on behaviour. 
Another methodological limitation of this study can be attributed to the nature of 
the behavioural task, and difficulty distinguishing locomotor behaviour exclusively from 
anxiety-like behaviour. It is possible that other tests of sickness and anxiety-like 
behaviour in rodents, such as those relating to social behaviour, may have yielded 
different results. As such, using other behavioural assays might be an effective way to 
resolve this limitation in the future. As OT has consistently been linked to mediation of 
social behaviours, such as social affiliation (Choleris et al., 2013; Ross & Young, 2009), 
and LPS induced sickness has been shown to affect social behaviour in rodents 
(Kavaliers & Choleris, 2011), it would be useful to employ social behavioural paradigms 
to examine OT’s effects on sickness behaviour in social contexts where OT mediated 
behaviours are more likely to be affected by social-contextual cues (Shamay-Tsoory & 
Abu-Akel, 2016). An example of this could be the social preference test, which is a well-
established model in animals for studying OT’s effects on social behaviour (Toth & 
Neumann, 2013). Another potential route could be to apply the socially based odor 
preference test to examine how OT affects sickness behaviour and pathogen avoidance in 
rodents (Arakawa et al., 2015; Kavaliers & Choleris, 2011). 
With respect to sex differences, OT may play a less important role in moderating 
behaviour in male animals, compared to females. In females, the estrous cycle has been 
shown to influence immune function and sickness behaviour in a manner that is 
dependent on estrous phase (Engeland et al., 2006). As such, future studies could 
examine effects of OT on sickness and anxiety-like behaviours more thoroughly in both 
males, and in females, by tracking estrous cycle to determine if and how OT differentially 
affects behavioural responses based on estrous hormone levels.   
2.4.5. Conclusions 
This study showed that treatment with the OT antagonist, L-368,899, attenuated 
sickness induced LPS perturbations in locomotor activity and anxiety-like behaviour, 
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effectively normalizing sickness behaviours. The exact mechanism by which this 
occurred remains to be elucidated. The present study demonstrates that OT antagonists do 
affect locomotor and anxiety-like behaviour related to sickness, and in particular that the 
absence of OT may lead to later onset of sickness behaviours, or perhaps suppress 
sickness behaviour altogether. It was also found that 10 mg/kg-saline treatment of the OT 
agonist, CBT, exerts suppressive effects on locomotor and anxiety-like behaviour in the 
LD test. Given that studies using OT antagonists tend to show increased anxiety-like 
behaviour in rodents, although a few studies have shown either no affect or anxiolytic 
effects, the finding that OT antagonist treatment augments locomotor activity and 
suppresses anxiety-like behaviour in male CD-1 mice is intriguing. Importantly, this 
finding illustrates that observed behavioural effects may be highly dose- and context-
related. Evidently, further research is needed to explore OT’s effects on behaviour, and in 
particular to distinguish any dose- and time-related effects of OT on sickness behaviour.  
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3.1 Introduction 
3.1.1. Oxytocin and Immune Function 
There is accumulating evidence suggesting that the nonapeptide, oxytocin (OT), is 
involved in the regulation of immune activity (eg. Wang et al., 2015). However, results of 
research focusing on relations between OT and immune function have been limited. 
Poutahidis et al. (2013) found that both endogenous OT and exogenous OT augmented 
wound healing capacity in male and female mice, and that wound healing in OT gene 
knockout mice was significantly improved following at least 3 days of peripheral OT 
treatment. As well, daily oral treatment with Lactobacillus reuteri, which interacts with 
the gut microbiome to up-regulate OT, was shown to accelerate wound healing by 
compressing the wound repair cascade, increasing collagen deposition, and importantly, 
by down-regulating the pro-inflammatory response (Poutahidis et al., 2013).  
Studies examining the type II transmembrane glycoprotein, CD38, further support 
the link between OT and immune function. CD38 plays a role in immune, social 
behavioural, and OT mediated functions (Algoe & Way, 2014; Feldman et al., 2016; 
Higashida et al., 2012; Jin et al., 2007; Lerer et al., 2010). In studies with mice, activities 
of immune-related cells, such as dendritic cells, monocytes, astrocytes, and neutrophils, 
are shown to be regulated by CD38 (Lund, 2006). In addition, neutrophil trafficking to 
sites of inflammation and infection is dependent upon CD38 expression on neutrophils 
(Partida-Sanchez et al. (2001). Among Autism Spectrum Disorder (ASD) patients, in 
which OT deficiencies have been extensively reported (Lukas & Neumann, 2013), 
abnormalities in CD38 expression may also point to a possible regulatory role of OT. 
Importantly, Lerer et al. (2010) found that lymphocytes from ASD patients had 
significantly less CD38 expression, compared to patients’ unaffected parents, providing 
further support for the integrated role of CD38 and OT in immune function and social 
behaviour. 
3.1.2. Oxytocin, Stress, and Immune Function 
The interplay between OT and the immune system may be mediated by the stress 
axis. OT has been shown to have suppressive effects on the stress response, reducing 
circulating levels of cortisol/corticosterone and adrenocorticotropic hormone (ACTH) 
(Brunton et al., 2012; Clodi et al., 2008; Detillion et al., 2004; DeVries et al., 2007; 
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Landgraf et al., 1995; Neumann et al., 2000). Higher HPA activation, and subsequently 
higher cortisol and ACTH, lead to increased levels of pro-inflammatory cytokines such as 
Tumor Necrosis Factor Alpha (TNF-) and Interleukin-6 (IL-6) (Anisman & Merali, 
2002). As such, OT's potential to dampen immune function via HPA mediated actions is 
an important consideration. 
In rodents, positive social interaction paradigms such as same-sex sibling pair 
housing, and pair bonding in monogamous prairie voles, were generally shown to 
augment endogenous OT levels and to reduce HPA activity and pro-inflammatory 
cytokines (DeVries et al., 2007). For instance, in extensive studies with adult female 
Siberian hamsters, Detillion et al., (2004) housed animals in pairs with a sibling, or 
individually, and the effects on wound healing were evaluated. They also manipulated 
OT levels by administering either OT (20 mg/kg i.p. for 5 days prior to wounding) or an 
OT antagonist (desGly-NH2-d(CH2)5(D-Tyr
2,Thr4]OVTa  at 3 l, intracerebroventricular 
(ICV), 1 day before wounding). Their results indicate that both OT treatment and positive 
social interaction promote wound healing via OT mediated mechanisms that suppress 
HPA activity in animals subjected to restraint stress (Detillion et al., 2004). Conversely, it 
was shown that female hamsters who received treatment with an OT antagonist or who 
were individually housed displayed increased HPA activity, pro-inflammatory cytokine 
activation, and inhibited wound healing (Detillion et al., 2004; DeVries et al., 2007; 
Neumann et al., 2000). Similarly, Vitalo et al. (2009) proposed that OT may facilitate 
wound healing through attenuation of the peripheral stress response similar to that seen in 
environmental enrichment paradigms. In their study, male Sprague-Dawley rats were 
reared in isolation and treated chronically with injections of OT (10 mg/kg i.p.) 5 days a 
week for 6 weeks, and/or received additional bedding as a means of environmental 
enrichment. They found that both OT and environmental enrichment facilitated wound 
healing rates comparably, suggesting both OT and environmental enrichment act in a 
similar manner to enhance wound healing, likely through attenuation of the peripheral 
stress response (Vitalo et al., 2009).  
3.1.3. OT, LPS, and Immune Function 
Lipopolysaccharide (LPS) is an endotoxin from the outer cell wall of Gram-
negative bacteria, which activates both the immune and endocrine systems, including the 
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HPA-axis, and increases pro-inflammatory cytokine levels in rodents (Anisman & 
Merali, 2002; Anisman et al., 2003) and humans (Clodi et al., 2008; Ross et al., 2013). A 
recent study by Yuan et al. (2016) found that in murine cells OT attenuated LPS induced 
microglial activation and pro-inflammatory cytokine levels. Furthermore, Reyes-Lagos et 
al. (2016) showed that in adult male rats treated with LPS, subcutaneous treatment with 
synthetic OT at 6g/kg moderated LPS-induced cytokine mediated hyperthermia (ie. 
fever). However, in contrast Ross et al. (2013) showed that in ex vivo experiments on 
healthy human monocytes and macrophages, OT did not attenuate LPS-induced cytokine 
production. 
While results of studies in non-human animals have established a link between 
LPS immune challenge and subsequent initiation of the stress response and immune 
activation (Anisman & Merali, 2002; Reyes-Lagos et al., 2016), relatively few studies 
have examined the effect of OT on immune function and its relation to the stress response 
in humans. Clodi et al., (2008) investigated the role of exogenous OT treatment on 
immune responses in men by administering an LPS immune challenge as an acute 
stressor. It was shown that among men treated intravenously with a dose of 1 
pmol/kg/min of OT plus 2 ng/kg of LPS for 90 minutes, there was an overall attenuation 
of typical LPS-induced increases in markers of HPA activation (ie. ACTH and cortisol), 
as well as in markers of immune activation (ie. TNF-, IL-1, IL-4, and IL-6). They 
concluded that OT was effective in attenuating neuroendocrine and pro-inflammatory 
cytokine activation caused by LPS treatment in men (Clodi et al., 2008). However, when 
Ross et al. (2013) examined OT’s effects on LPS activated healthy human monocytes and 
macrophages they found that OT did not attenuate pro-inflammatory cytokines. This led 
them to conclude that the anti-inflammatory effects of OT observed in other studies may 
be dependent on other classes of immune cells or lymphoid organs. These contradictory 
findings thus indicate the need for further investigations of the relations between OT, 
stress, LPS, and immune function.  
3.1.4. Present Study 
In the present study, effects of the OT agonist, carbetocin, and OT antagonist, L-
368,899, on pro-inflammatory cytokine levels of TNF-and IL-6 following LPS 
administration were evaluated. On the basis of limited previous studies, it was 
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hypothesized that the OT agonist would result in reduced serum levels of pro-
inflammatory cytokines TNF- and IL-6 among animals treated with LPS, while the OT 
antagonist was anticipated to augment levels of these cytokines.  
3.2 Methods 
3.2.1. Animals 
The same animals used in experiment 1 were also used in this study. A total of 41 
adult male CD-1 mice (30 to 35 grams) from Charles River, Quebec, were used to study 
the effects of the OT agonist, CBT, while another 31 adult male CD-1 mice were used to 
evaluate effects of the OT antagonist, L-368,899. Animals were housed in a temperature 
controlled colony room at 211°C, with photoperiod set to a 12:12 Light:Dark cycle with 
lights on at 0700, and were provided food (ProLab rodent chow, RMH 3000) and water 
ad libitum. Animals were housed individually in polypropylene cages (29.5 x 18.8 x 13 
cm). Effects of individual housing on male mice are strain and density dependent, with 
previous studies showing negligible differences in CD-1 mice with regard to basal stress 
responses between individually and socially housed males (Bartolomucci, 2007; 
Bartolomucci et al., 2003). However, individual housing was used in this study to prevent 
effects of inter-male aggression and minimize dominance-subordinance related 
differences in individual stress and OT responses, as social contextual variables have 
been shown to affect these (Choleris et al., 2013; DeVries et al., 2007). Mice were left 
undisturbed for 10 days prior to testing to ensure adequate adjustment time after arrival.  
All procedures were approved by the Western University Animal Care Committee and 
animals were handled and tested according to guidelines set out by the Canadian Council 
on Animal Care (CCAC).    
3.2.2. Drug Treatment – OT Agonist: Carbetocin 
Mice were randomly divided into 6 groups. Beginning between 12:00 and 13:00h, 
all animals received a series of 2 intraperitoneal (i.p.) injections, 15 minutes apart. Table 
3.1 outlines the group treatments and group sizes. The first injection manipulated OT 
levels. Here, 2 groups received a 20mg/kg dose of OT agonist, carbetocin (CBT) 
(Carbetocin acetate SML0748, no. 073M4722V, Sigma-Aldrich, St. Louis, MO, USA) 
dissolved in 0.9% isotonic saline, while 2 other groups received a 10mg/kg dose, and the 
remaining 2 groups were administered a control injection of an equivalent volume of 
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isotonic saline (0.9%). CBT was chosen as the OT agonist for its relatively long half-life 
(85 – 100 mins) (Engstrøm et al., 1998; Moertl et al., 2011) and the doses were based on 
behaviourally active doses previously reported in mice (eg. Chaviaras et al., 2010). The 
second injection 15 mins later initiated an immune challenge. Animals received either 75 
g/kg Lipopolysaccharide (LPS) (derived from Escherichia Coli serotype 0111:B4, no. 
L2630-028K4090, Sigma Chemical, St. Louis, MO, USA) dissolved in a 0.9% isotonic 
saline, or an equivalent volume of saline as a control. This dose of LPS was selected 
based on previous work done in CD-1 mice (Engeland et al., 2001).   
Table 3.1. Group sizes and treatment injections for OT agonist and LPS 
Group Injection 1 Injection 2 n:   
TNF- 
assay 
n:  
IL-6 
assay 
20CBT-LPS 20 mg/kg carbetocin g/kg LPS 5 5 
10CBT-LPS 10 mg/kg carbetocin g/kg LPS 11 7 
20CBT-NaCl 20 mg/kg carbetocin 0.2 to 0.35 mL saline 4 4 
10CBT-NaCl 10 mg/kg carbetocin 0.2 to 0.35 mL saline 12 12 
NaCl-LPS 0.2 to 0.35 mL saline g/kg LPS 5 3 
NaCl-NaCl 0.2 to 0.35 mL saline 0.2 to 0.35 mL saline 4 4 
 
3.2.3. Drug Treatment – OT Antagonist: L-368,899  
Mice were randomly divided into 4 groups. Beginning between 12:00 and 13:00h, 
all animals received a series of 2 intraperitoneal (i.p.) injections, 15 minutes apart. Table 
3.2 outlines the group treatments and group sizes. First, 2 groups received a 10mg/kg 
dose of the OT antagonist, L-368,899 (L-368,899 hydrochloride, no. 1A/82628, Tocris 
Bioscience, Minneapolis, MN, USA) dissolved in 0.9% isotonic saline. The other 2 
groups were administered an equivalent volume of isotonic saline (0.9%) for their first 
injection. Previous studies have shown L-368,899, at varying dosages, to be an effective 
OT antagonist in mice and the dose used here was based on these studies (Kuteykin-
Teplyakov & Maldonado 2014; Olszewski et al., 2015; Olszewski et al., 2014). The 
second injection 15 mins later initiated an immune challenge. Animals received either 75 
g/kg Lipopolysaccharide (LPS) (derived from Escherichia Coli serotype 0111:B4, no. 
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L2630-028K4090, Sigma Chemical, St. Louis, MO, USA) dissolved in a 0.9% isotonic 
saline, or saline as a control. This dose was selected based on previous work done in    
CD-1 mice (Engeland et al., 2001). 
Table 3.2. Group sizes and treatment injections for OT antagonist and LPS 
Group Injection 1 Injection 2 n: TNF- 
assay 
n: IL-6 
assay 
OTant-NaCl 10 mg/kg L-368,899 0.2 to 0.35 mL saline 10 10 
OTant-LPS 10 mg/kg L-368,899 g/kg LPS 10 10 
NaCl-LPS 0.2 to 0.35 mL saline g/kg LPS 6 4 
NaCl-NaCl 0.2 to 0.35 mL saline 0.2 to 0.35 mL saline 5 5 
 
3.2.4. Procedure 
After behavioural testing (as described in experiment 1), approximately 4 hours 
after LPS treatment and within 20 minutes of removal from the VersaMax activity box, 
animals were killed via cervical dislocation followed by immediate decapitation. Trunk 
blood samples of approximately 0.5mL were collected, placed on ice, and then 
centrifuged at 3000 RPM for 10 minutes. Serum were separated from red blood cells and 
frozen at -80 degrees until needed for cytokine assays. TNF- and IL-6 were analyzed in 
parallel using Luminex Mouse Cytokine /Chemokine Magnetic Bead kits manufactured 
by EMD Millipore Corporation (Billerica, MA 01821 USA) according to manufacturer 
instructions, as seen in Appendix A. IL-1 was also analyzed, however these values were 
out of range and thus were not included for further analysis. Assay sensitivity was 
determined using the Minimum Detectable Concentration (MinDC), and was calculated 
with MILLIPLEX® Analyst 5.1. For TNF- the MinDC is 2.3 pg/mL, while the 
MinDC+2SD is 3.4 pg/mL. For IL-6 the MinDC is 1.1 pg/mL, while the Min DC+2SD is 
2.0 pg/mL. Accuracy for the TNF- and IL-6 assays were calculated at 94%, and 92.2%, 
respectively.  
3.2.5. Data Analysis 
The effects of the OT agonist, CBT, OT antagonist, L-368,899, and LPS on pro-
inflammatory cytokines TNF- and IL-6, were each evaluated using a univariate 
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Analysis of Variance (ANOVA) with between subjects factors of CBT (3 levels: 
20mg/kg CBT, 10mg/kg CBT, saline (control)), or OT antagonist (2 levels: 10mg/kg OT 
antagonist, saline (control)) and LPS (2 levels: g/kg and saline (control)). Post hoc 
pairwise comparisons were then completed, where appropriate, using the Least 
Significant Difference (LSD) to evaluate significant main effects and interactions. Tests 
of polynomial linear contrasts were also conducted to examine potential linear 
relationships within the data. Data were analyzed using SPSS 23.0 for windows with  = 
0.05, and the Greenhouse-Geisser correction factor where appropriate. 
3.3 Results 
3.3.1. LPS and OT Agonist Effects on Cytokines 
Serum concentrations of TNF- for animals treated with LPS and the OT agonist, 
CBT, are shown in Figure 3.1. ANOVA analysis revealed a significant main effect of 
LPS [F(1, 35) = 47.54, p = .000], such that LPS treated animals showed significantly 
higher serum concentrations of TNF- relative to non-LPS treated groups (p’s < .001). 
This is suggestive of pro-inflammatory cytokine induced inflammation.  
No significant main effects of CBT treatment were found [F(2, 35) = 1.67, p = 
.202], indicating that OT agonist treatment did not significantly influence TNF- serum 
concentration levels. Furthermore, linear contrasts were non-significant demonstrating a 
lack of a linear relationship between CBT dose and TNF- serum concentrations (p = 
.265).  
No significant interactions were observed [F(2, 35) = .69, p = .510]; However, 
planned comparisons were conducted to examine potential dose-related differences 
among individual groups. Post hoc analysis revealed dose-related effects of CBT as the 
10mg/kg CBT-LPS, but not the 20mg/kg CBT-LPS group, had significantly greater 
serum concentration levels of TNF- relative to saline-LPS treated mice (p = .045).  
 Serum concentrations of IL-6 for animals treated with LPS and the OT agonist, 
CBT, are shown in Figure 3.2.The ANOVA revealed a significant main effect of LPS 
[F(1, 29) = 51.32, p = .000] for serum concentrations of IL-6. LPS treated animals had 
significantly higher concentrations of pro-inflammatory cytokine IL-6 relative to non-
LPS groups (p’s < .001), indicating inflammation.  
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The analysis found no significant main effects of CBT treatment [F(2, 29) = 1.71, 
p = .198] on IL-6 serum concentrations. This shows that OT agonist treatment has no 
significant effect on IL-6 pro-inflammatory cytokine levels. Furthermore, non-significant 
linear contrasts indicated no significant linear relationship between CBT dose and IL-6 
serum concentrations (p = .375). 
 Significant interactions for effects on IL-6 serum levels were not observed [F(2, 
29) = 1.93, p = .163]; However, planned comparisons were nevertheless conducted to 
evaluate potential dose-related differences among groups. Post hoc analysis revealed 
effects of the OT agonist treatment as both the 10mg/kg CBT-LPS (p = .034) and the 
20mg/kg CBT-LPS (p = .023) treated groups had significantly higher serum 
concentrations of  IL-6 relative to saline-LPS treated mice.  
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Fig. 3.1. Mean TNF- serum concentrations (pg/mL) for mice treated i.p. with the OT agonist, 
CBT, plus LPS or saline. Vertical lines indicate standard error. LPS groups showed significantly 
higher serum levels of TNF- relative to non-LPS groups (p < .001; not marked on graph), 
indicating LPS-induced inflammation. 10mg/kg CBT-LPS treated mice had significantly higher 
serum levels of TNF- than saline-LPS treated mice (@ p < .05).  
 
Fig. 3.2. Mean IL-6 serum concentrations (pg/mL) for mice treated i.p. with the OT agonist, 
CBT, plus LPS or saline. Vertical lines indicate standard error. LPS groups showed significantly 
higher serum levels of IL-6 relative to saline groups (p < .001; not marked on graph), indicative 
of LPS-induced inflammation. Both 10mg/kg CBT-LPS and 20mg/kg CBT-LPS (@ p < .05) 
treated groups had significantly higher serum concentrations of  IL-6 relative to saline-LPS 
treated mice.  
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3.3.2. LPS and OT Antagonist Effects on Cytokines 
 Serum concentrations of TNF- for animals treated with LPS and the OT 
antagonist, L-368,899, are shown in Figure 3.3. A significant main effect of LPS was 
found [F(1, 27) = 38.16, p = .000]. LPS treated mice had significantly higher serum 
concentrations of TNF- relative to saline treated groups (p’s < .001), suggesting LPS-
induced inflammation. 
 Significant main effects of OT antagonist treatment were not found [F(1, 27) = 
1.16, p = .292], indicating that OT antagonist treatment did not significantly affect TNF-
 serum concentration levels. ANOVA analysis revealed no significant OT antagonist x 
LPS interactions [F(1, 27) = 1.16, p = .291].  
 IL-6 serum concentrations for animals treated with LPS and the OT antagonist, L-
368,899, are shown in Figure 3.4. ANOVA analysis revealed a significant main effect of 
LPS treatment [F(1, 25) = 36.25, p = .000] for IL-6 serum concentrations. Relative to 
saline treated animals, LPS treated mice had significantly higher serum concentrations of 
pro-inflammatory cytokine IL-6 (p’s < .001), indicative of LPS induced inflammation. 
 No significant main effects of OT antagonist treatment on IL-6 serum 
concentrations were found [F(1, 25) = .14, p = .716]; suggesting that OT antagonist 
treatment did not significantly affect IL-6 pro-inflammatory cytokines. Furthermore, 
significant OT antagonist x LPS interactions for effects on IL-6 serum levels were not 
observed [F(1, 25) = .00, p = .987]. 
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Fig. 3.3. Mean TNF- serum concentrations (pg/mL) for mice treated i.p. with the OT 
antagonist, L-368,899, plus LPS or saline. Vertical lines indicate standard error. LPS 
groups showed significantly higher serum levels of TNF- relative to non-LPS groups (p 
< .001; not marked on graph). 
 
Fig. 3.4. Mean IL-6 serum concentrations (pg/mL) for mice treated i.p. with the OT 
antagonist, L-368,899, plus LPS or saline. Vertical lines indicate standard error. LPS 
groups showed significantly higher serum levels of IL-6 relative to saline groups (p’s < 
.001; not marked on graph). 
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3.4 Discussion 
3.4.1. Effects of LPS on Cytokines 
The current study examined the effects of the OT agonist, CBT, and the OT 
antagonist, L-368,899, on serum concentrations of TNF- and IL-6 in male CD-1 mice 
following treatment with LPS (75 g/kg i.p.). LPS treatment robustly and consistently 
augmented serum levels of both TNF- and IL-6, thereby confirming and extending the 
results of previous research (Anisman & Merali, 2002; Anisman et al., 2003). All LPS 
treated groups showed significantly higher concentrations of both cytokines relative to 
non-LPS treated animals, thus indicating that the immunoassay was providing reliable 
measures that were consistent with cytokine values obtained from other studies (Hubner 
et al., 2008; Iseri et al., 2010; Starkhammer et al., 2012). For example, Hubner et al. 
(2008) found that in both male and female adult mice treated with LPS there was a 
significant increase in levels of pro-inflammatory cytokines, including IL-6 and TNF-, 
which persisted for up to between 1 to 48 hours after LPS challenge.  
3.4.2. Effects of OT on Cytokines 
 Neither the OT agonist, CBT, nor the OT antagonist, in conjunction with saline, 
had significant effects on basal levels of either TNF- or IL-6. This finding suggests that 
OT does not affect these cytokines in the absence of LPS treatment. In the context of 
immune challenge via injury or infection (eg. LPS), results from the present study 
contrast with those from previous limited research. For example, Iseri et al. (2010) 
showed that OT treatment at 5 mg/kg (s.c.) twice a day for 5 days attenuated basal TNF-
 at day 5 following burn injury. Furthermore, Clodi et al. (2008) found that in men 
intravenous LPS treatment in conjunction with OT attenuated serum levels of pro-
inflammatory cytokines, including TNF- and IL-6.  
Despite the lack of significance found for OT’s effects on cytokines in the current 
study, planned comparisons were conducted to explore potential dose-related effects of 
the OT agonist treatment when combined with LPS. Mice treated with 10 mg/kg CBT-
LPS, but not 20 mg/kg CBT-LPS, showed significantly higher plasma concentrations of 
TNF- relative to saline-LPS treated mice. This finding contrasts with those of previous 
studies which have shown that OT treatment tends to decrease serum levels of pro-
inflammatory cytokines (Clodi et al., 2008; Wang et al., 2015; Yuan et al., 2016). 
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However, others indicate that in vivo, OT does not attenuate pro-inflammatory cytokines 
(Ross et al., 2013). It is not clear then, the impact that OT has on serum levels of TNF- 
and further studies are needed to clarify these effects.  Furthermore, the present data 
suggest that OT’s effects on TNF- may be dose-related. As previous studies have not 
examined dose-related effects of OT on serum TNF- levels, additional studies are 
needed to clarify any dose-related effects of OT on TNF- immune functions.  
OT agonist treatment had no suppressive effects on serum levels of IL-6 in LPS 
treated mice. In both the 10 mg/kg CBT-LPS and the 20 mg/kg CBT-LPS treated groups 
there were significantly higher serum concentrations of IL-6 compared to saline-LPS 
treated mice. This finding is in contrast to previous studies which have shown that OT 
agonist treatment tends to decrease serum levels of pro-inflammatory cytokines, such as 
IL-6 (Clodi et al., 2008; Wang et al., 2015; Yuan et al., 2016). Other studies (eg. Ross et 
al., 2013), however, have shown that in vivo, OT does not attenuate pro-inflammatory 
cytokines. Together, these findings highlight that OT’s effects on pro-inflammatory 
cytokines, such as IL-6, are still not clearly understood and that further research is needed 
to characterize the nature of these effects.   
3.4.3. Limitations and Future Directions 
In light of previous research, findings from the current study are intriguing. In 
particular, OT treatment has generally been associated with attenuations in pro-
inflammatory cytokine levels, while OT antagonist treatment seems to augment levels of 
pro-inflammatory cytokine activation (Wang et al., 2015). However, previous studies did 
not specifically examine the effects of systemic OT on cytokines in the context of LPS 
treatment, but rather evaluated i.p. or ICV administered OT or OT antagonist treatment 
effects on subcutaneous wound healing as an index of immune function (Detillion et al., 
2004; Iseri et al., 2010). As such, it is possible that OT differentially affects immune 
responses dependent on the type and magnitude of injury or infection, and route of OT 
administration. Future research should evaluate the role of OT on immune function using 
a variety of infection types and severities, as well as by comparing systemic versus 
central OT treatment routes. 
Another potential confound that may have obscured OT’s effects on TNF- and 
IL-6 in the present study is the large degree of variability among group sizes coupled 
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with some rather small samples, which likely increased variability in the data. Future 
studies could resolve this issue by increasing and equalizing group sizes to produce more 
consistent data with less variability. The present study was also conducted following 
behavioural testing. Although attempts were made to ensure animals were as stress-free 
as possible, behavioural activity and subsequent arousal undoubtedly caused some degree 
of anxiety among mice, which would likely confound cytokine activity via HPA 
mediated mechanisms. Future research could circumvent this limitation by using separate 
animals for behavioural versus immunological testing.  
3.4.4. Conclusions 
 The present study both confirmed and extended knowledge pertaining to OT’s 
role in immune function by examining effects of the OT agonist, CBT, and the OT 
antagonist, L-368,899, on cytokines TNF- and IL-6, in conjunction with LPS treatment. 
The LPS immune challenge predictably produced robust pro-inflammatory responses as 
indicated by increased levels of both TNF- and IL-6. However, OT failed to produce 
any significant suppressive effects on levels of these cytokines, although dose-related 
effects of OT agonist treatment were observed among LPS treated mice. In light of 
previous research, which has investigated OT’s role regarding pro-inflammatory 
cytokines in the context of subcutaneous wound healing (eg. Detillion et al., 2004; Iseri et 
al., 2010), in vivo experiments (Ross et al., 2013), and most recently in conjunction with 
LPS immune challenge (Yuan et al., 2016), the present results were curious. As neither 
the OT agonist nor the OT antagonist had any significant effect on mediating pro-
inflammatory cytokines, the present study indicates that OT’s role in immune function 
may be dependent on the type and severity of infection, administration route, and dose.  
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4.1 General Discussion 
The present study examined the effects of OT manipulations on the expression of 
LPS-induced sickness behaviours, including anxiety and locomotor behaviour, and 
immune function. Adult male CD-1 mice were treated with the OT agonist, carbetocin, or 
the OT antagonist, L-368,899, in conjunction with LPS immune challenge, and the 
effects on locomotor and anxiety-like behaviour, as well as pro-inflammatory cytokines 
TNF- and IL-6, were evaluated. It was found that treatment with the OT antagonist, L-
368,899, attenuated LPS induced perturbations in locomotor and anxiety-like behaviour. 
In contrast, the OT agonist, carbetocin, had no effect on locomotor and anxiety-related 
sickness behaviours. However, effects on basal locomotor and anxiety-like behaviour 
were found for some measures for both the OT agonist and antagonist.  
The current results were interesting in light of findings from previous research, 
which has investigated OT’s role in immune activation in the context of subcutaneous 
wound healing (eg. Detillion et al., 2004), and most recently in conjunction with LPS 
immune challenge and behaviour (Reyes-Lagos et al., 2016; Yuan et al., 2016). 
Importantly, results of previous studies have generally shown that OT reduces cytokine 
activation and in the case of the Reyes-Lagos et al., (2016), rescues LPS induced 
perturbations in locomotor behaviour. In the present study, cytokine assays showed that 
LPS treatment produced a robust pro-inflammatory response as indicated by increased 
serum levels of both TNF- and IL-6. Although dose-related effects of CBT were 
observed, neither the OT agonist, nor the OT antagonist, produced any significant effects 
on levels of these cytokines, which could be a function of the large degree of variability 
in that data, small sample sizes, or perhaps due to a floor effect. Regardless, 
behaviourally speaking the present study demonstrates that systemic treatment with an 
OT antagonist attenuates the expression of locomotor and anxiety-related sickness 
behaviour, perhaps via delaying the onset, or by suppressing behavioural expressions of 
sickness altogether.  
4.1.1. Effects of OT Agonist Treatment 
In the present study, treatment with 10 mg/kg of the OT agonist, CBT, plus saline, 
had suppressive effects on locomotor and anxiety-like behaviour in the LD test. The 10 
mg/kg CBT treatment led to reduced locomotor activity overall. This effect was not 
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observed among the 20 mg/kg CBT or saline-control groups, suggesting that the 10 
mg/kg CBT dose suppressed locomotor activity in a non-novel context. Interestingly, the 
10 mg/kg CBT group also demonstrated a reduced number of transitions into the light 
chamber, which is a more anxiogenic context (Bourin & Hascoet, 2003), relative to the 
20 mg/kg CBT group. This suggests that the 10 mg/kg dose of CBT augmented anxiety-
like responses and reduced exploratory behaviour in this context. To some degree, the 
present findings contrast with those of previous studies. For instance, Ring et al. (2006) 
found that 10 mg/kg (i.p.) of OT 30 minutes prior to testing led to anxiolytic effects of 
peripheral OT on behaviour. Chaviaras et al. (2010) found that male rats treated with a 
high (ie. 20 mg/kg) but not low (ie. 2 mg/kg; 6.4 mg/kg) dose (i.p.) of OT agonist, 
carbetocin, 30 minutes prior to testing showed a significant decrease in total distances 
animals’ travelled, suggesting suppressed locomotor activity and increased anxiety in the 
open field test.  
The differences observed between the results of the present study and those of 
others could be attributed to the amount of time elapsed between OT administration and 
commencement of behavioural testing, as well as species and/or test-specific differences. 
Furthermore, these differential findings illustrate the dose-related differences in effects 
on anxiety-like behaviour in male rodents. In the present study, behavioural testing did 
not occur until 2 hours after OT agonist treatment. This may suggest that temporal 
variables play a role in mediating OT’s effects on anxiety-like behaviour. Specifically, 
OT may exert anxiolytic effects shortly after treatment, as seen in other studies (eg. Ring 
et al. 2006), and anxiogenic effects in a dose-related manner following longer time delays 
between administration and testing, as seen in the present study. In the context of 
previous research, results of this study demonstrate the dose-related and potentially 
temporally-dependent nature of anxiolytic and anxiogenic effects of OT on behaviour. 
Furthermore, the existing ambiguity in findings illustrate the need for further research to 
explore OT agonist effects on behaviour, and to distinguish potential dose-and time-
related effects of OT on sickness behaviour.  
4.1.2. Effects of OT Antagonist Treatment 
In the present study, treatment with the OT antagonist, L-368-899, at a 10mg/kg 
(i.p.) dose was found to augment locomotor and exploratory behaviour in male CD-1 
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mice. Furthermore, OT antagonist treatment resulted in mice spending significantly more 
time in the light chamber of the light-dark test, and making more Nose Pokes and 
Transitions into the light chamber, indicating an overall reduction in anxiety-like 
behaviour. These results are intriguing as previous research often attributes OT antagonist 
treatment with anxiogenic effects on behaviour (Neumann & Landgraf, 2012; Olszewski 
et al., 2014). For example, findings from a study by Ring et al. (2006) show that the OT 
antagonist, WAY-162720, at 10 mg/kg (i.p.) 30 minutes prior to testing lead to 
anxiogenic effects on behaviour in male mice. However, more recent studies have also 
shown effects consistent with that of the present study, as others have found that OT 
antagonist treatment has anxiolytic effects in certain contexts. For instance, Duque-
Wilckens et al. (2016) showed that in female mice treated with L-368,899 (i.p.) 30 min 
before behavioural testing, the OT antagonist blocked the effects of stress in both the 
social interaction and odor preference tests, such that animals showed high levels of 
social interaction, and preferred the odor of an unfamiliar individual. Conversely, when 
stressed, saline treated mice showed reduced social interaction and a preference for the 
odor of a familiar cagemate, suggesting that OT antagonist treatment has anxiolytic 
effects on behaviour in social contexts (Duque-Wilckens et al., 2016). Guzman et al. 
(2014) showed that in male mice OT receptor function appears to exert bidirectional 
effects on anxiety-like behaviour related to social fear, as OT appears to decrease anxiety 
following positive, but increase anxiety after negative, social encounters. Importantly, it 
was shown that OT antagonist treatment to the lateral septum of mice abolished 
anxiogenic behaviour during fear conditioning, suggesting that OT antagonists have 
anxiolytic effects on anxiety-like behaviour in social contexts (Guzman et al., 2014). 
Therefore, it is possible that in the current study the OT antagonist reduced anxiety-like 
behaviour in male mice due to context-dependent effects, and that the 2 hour time delay 
between drug administration and behavioural testing also influenced effects on anxiety-
like behaviour.  
4.1.3. LPS and OT Effects on Cytokines  
The present study showed that LPS treatment robustly increased serum levels of 
both TNF- and IL-6, indicating inflammation, as all LPS treated groups showed 
significantly higher concentrations of both cytokines relative to non-LPS treated animals. 
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Neither the OT agonist, CBT, nor the OT antagonist, significantly affected serum levels 
of TNF- or IL-6 in saline controls, suggesting that OT does not affect these cytokines in 
absence of LPS treatment. However, further analyses showed that animals treated with 10 
mg/kg CBT-LPS, but not 20 mg/kg CBT-LPS, had significantly higher serum 
concentrations of TNF- relative to saline-LPS treated mice. These results are suggestive 
of OT’s effects on TNF- being dose-related, though further studies are needed to clarify 
any dose-related effects. Effects of OT agonist treatment in conjunction with LPS were 
also observed for IL-6. However, dose-related effects were not observed in this case as 
both CBT-LPS treated groups showed significantly higher serum concentrations of IL-6 
compared to saline-LPS treated mice. Previous research suggests that OT treatment tends 
to decrease serum levels of pro-inflammatory cytokines, such as TNF- and IL-6 (Clodi 
et al., 2008; Wang et al., 2015; Yuan et al., 2016), while other studies such as that done 
by Ross et al. (2013) have shown that OT does not attenuate pro-inflammatory cytokines. 
Evidently, further research is needed to elucidate the effects and mechanisms by which 
OT influences inflammation, since considerable variability between studies remains 
regarding OT’s effects on pro-inflammatory cytokines.  
4.1.4. Limitations and Future Research 
Methodological limitations in the present study may account for the results 
observed. In particular, since there are relatively few existing studies in mice with which 
to determine dosages, calculating the dose of OT drugs to be used here was challenging. 
As well, the 2 hour time delay between OT drug administration and testing may have 
differentially affected behavioural and cytokine outcomes. In the majority of previous 
studies, there is often only a 30 minute time delay between OT treatment and subsequent 
testing due to the relatively short half-life of OT (eg. Chaviaras et al., 2010; Ring et al., 
2006). Therefore, in the present study behavioural and immune effects of OT may have 
been complicated due to lower systemic levels of OT, potentially reducing its effects on 
behaviour and cytokines. Future research could examine OT’s effects on sickness and 
anxiety-like behaviour, as well as cytokines, at varying dosages to elucidate dose-related 
effects of OT in mice. As well, examining OT’s effects on sickness and anxiety-like 
behaviours and cytokines at different time points after drug administration may be useful 
in clarifying time-related effects of OT.  
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The nature of the behavioural task used in this study is another potential 
methodological limitation that could be addressed in future studies. In particular, the 
light-dark test presents a challenge in that it can be difficult to distinguish locomotor 
behaviour exclusively from anxiety-like behaviour. As such, using other behavioural 
assays that can more clearly distinguish anxiety and sickness-related behaviours might be 
a way to resolve this potential limitation in the future. Since numerous studies have 
shown that OT is strongly associated with the mediation of social behaviours, such as 
social affiliation (Choleris et al., 2013; Ross & Young, 2009), and LPS induced sickness 
has been shown to affect social behaviour in rodents (Arakawa et al., 2015; Kavaliers & 
Choleris, 2011), future studies should apply social behavioural paradigms, such as the 
social interaction or odor preference tests, to investigate OT’s effects on anxiety and 
sickness behaviour in social contexts where OT mediated behaviours are more likely to 
be affected (Guzman et al., 2013; Shamay-Tsoory & Abu-Akel, 2016).  
Stress experienced during behavioural testing, as well as small and uneven 
treatment group sizes, may have adversely influenced results of the cytokine assays. 
While attempts were made to ensure that animals were comfortable, handling stress, 
isolation housing, and behavioural testing would undoubtedly have caused some degree 
of distress among mice. This stress may have confounded cytokine activity via HPA 
mediated mechanisms, as HPA activity has previously been shown to increase levels of 
pro-inflammatory cytokines (Anisman & Merali, 2002), potentially creating a ceiling 
effect. This limitation could be circumvented in future studies by using separate animals 
for behavioural versus immunological testing, as well as increasing and equalizing group 
size numbers. 
In the present study only male animals were used due to time constraints and the 
potential confounding effects of the estrous cycle in females. Future research could more 
thoroughly examine OT’s effects on anxiety and sickness-related behaviour in both males 
and females, by tracking the estrous cycle in females. Previous studies have shown that 
the estrous cycle influences immune function and sickness behaviour in a manner that is 
dependent on estrous phase (Engeland et al., 2006). As such, investigating the effects of 
OT on sickness behaviours in females at specific points in the estrous cycle may reveal 
important hormone-related effects of OT on behavioural responses and immune function. 
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Literature on the role of cytokines in relation to anxiety remains quite sparse. 
However, a limited number of studies have shown a link between levels of pro-
inflammatory cytokines and anxiety-like behaviour in rats and mice. For example, 
Ramirez et al. (2016) found that in male mice treated daily with 15mg/kg (orally) of the 
anti-depressant, imipramine, there was an attenuation of social defeat stress-induced 
corticosterone and IL-6 levels in serum, with corresponding reductions in anxiety-like 
behaviour in the open field test. Furthermore, in another study it was shown that daily 
treatment with 20mg/kg (i.p.) of imipramine in male mice subjected to repeated social 
defeat stress, there was an increase in social interaction time indicating reduced social 
anxiety, with corresponding reductions brain levels of pro-inflammatory cytokine, IL-6 
(Ramirez et al., 2015). Furthermore, in response to LPS immune challenge, Ramirez et al. 
(2015) also found that imipramine reduced levels of TNF-, IL-6, and IL-1 in the brain 
microglia of mice subjected to social defeat stress. These studies clearly demonstrate a 
link between stress-induced pro-inflammatory cytokines and anxiety-like behaviour in 
social contexts, with a potential role for OT. As such, future research should be 
conducted to better understand the link between pro-inflammatory cytokines, anxiety, and 
sickness-related behaviour, along with the potential role for OT in mediating these 
behaviours and immune function.   
4.1.5. Conclusions 
The present study showed that treatment with the OT antagonist, L-368,899, 
attenuates the expression of  LPS-induced perturbations in locomotor activity and 
anxiety-like sickness-related behaviour, effectively normalizing these particular sickness 
behaviours. However, neither the OT agonist, nor the OT antagonist, produced any 
significant effects on serum TNF- and IL-6 levels. Together, these findings demonstrate 
that systemic treatment with an OT antagonist attenuates the expression of locomotor and 
anxiety-related sickness behaviours, perhaps by delaying the onset or suppressing 
sickness behaviour altogether, and that this effect may be independent of cytokine 
mediated mechanisms. As such, this study provides evidence that OT antagonists may be 
efficacious in treating some behavioural symptoms of sickness, such as lethargy and 
anxiety. Results of this study also suggest that OT antagonists may have potential as 
anxiolytic treatments. However, in consideration of the present findings along with that 
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of previous research, further research is justified as the precise effects of, and 
mechanisms by which, OT influences anxiety, sickness behaviour, and immune function 
remain to be elucidated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
4.2 References 
Anisman, H., & Merali, Z. (2002). Cytokines, stress, and depressive illness. Brain, 
Behavior, and Immunity, 16(5), 513-524. doi:10.1016/s0889-1591(02)00009-0 
Arakawa, H., Blanchard, D. C., & Blanchard, R. J. (2015). Central oxytocin regulates 
social familiarity and scent marking behavior that involves amicable odor signals 
between male mice. Physiology & Behavior, 146, 36-46. 
doi:10.1016/j.physbeh.2015.04.016 
Bourin, M., & Hascoët, M. (2003). The mouse light/dark box test. European Journal of 
Pharmacology, 463(1-3), 55-65. doi:10.1016/s0014-2999(03)01274-3 
Chaviaras, S., Mak, P., Ralph, D., Krishnan, L., & Broadbear, J. H. (2010). Assessing the 
antidepressant-like effects of carbetocin, an oxytocin agonist, using a 
modification of the forced swimming test. Psychopharmacology, 210(1), 35-43. 
doi:10.1007/s00213-010-1815-x 
Choleris, E., Pfaff, D. W., & Kavaliers, M. (2013). Oxytocin, vasopressin and related 
peptides in the regulation of behavior. New York: Cambridge University Press. 
Clodi, M., Vila, G., Geyeregger, R., Riedl, M., Stulnig, T. M., Struck, J., . . . Luger, A. 
(2008). Oxytocin alleviates the neuroendocrine and cytokine response to bacterial 
endotoxin in healthy men. AJP: Endocrinology and Metabolism, 295(3). 
doi:10.1152/ajpendo.90263.2008 
Detillion, C. E., Craft, T. K., Glasper, E. R., Prendergast, B. J., & Devries, A. (2004). 
Social facilitation of wound healing. Psychoneuroendocrinology, 29(8), 1004-
1011. doi:10.1016/j.psyneuen.2003.10.003 
DeVries, A. C., Craft, T. K., Glasper, E. R., Neigh, G. N., & Alexander, J. K. (2007). 
2006 Curt P. Richter award winner: Social influences on stress responses and 
health. Psychoneuroendocrinology, 32(6), 587-603. 
doi:10.1016/j.psyneuen.2007.04.007 
 
 
83 
 
Duque-Wilckens, N., Steinman, M. Q., Tan, P. B., Hao, R., & Trainor, B. C. (2016). 
Systemic inhibition of oxytocin receptors blocks stress induced social anxiety in 
female California mice [Abstract]. Society For Neuroscience. 
Engeland, C. G., Kavaliers, M., & Ossenkopp, K. (2006). Influence of the estrous cycle 
on tolerance development to LPS-induced sickness behaviors in rats. 
Psychoneuroendocrinology, 31(4), 510-525. doi:10.1016/j.psyneuen.2005.11.007 
Guzmán, Y. F., Tronson, N. C., Jovasevic, V., Sato, K., Guedea, A. L., Mizukami, H., . . . 
Radulovic, J. (2013). Fear-enhancing effects of septal oxytocin receptors. Nature 
Neuroscience, 16(9), 1185-1187. doi:10.1038/nn.3465 
Guzmán, Y. F., Tronson, N. C., Sato, K., Mesic, I., Guedea, A. L., Nishimori, K., & 
Radulovic, J. (2014). Role of oxytocin receptors in modulation of fear by social 
memory. Psychopharmacology, 231(10), 2097-2105. doi:10.1007/s00213-013-
3356-6 
Kavaliers, M., & Choleris, E. (2011). Sociality, pathogen avoidance, and the 
neuropeptides oxytocin and arginine vasopressin. Psychological Science, 22(11), 
1367-1374. doi:10.1177/0956797611420576 
Neumann, I. D., & Landgraf, R. (2012). Balance of brain oxytocin and vasopressin: 
Implications for anxiety, depression, and social behaviors. Trends in 
Neurosciences, 35(11), 649-659. doi:10.1016/j.tins.2012.08.004 
Olszewski, P. K., Ulrich, C., Ling, N., Allen, K., & Levine, A. S. (2014). A non-peptide 
oxytocin receptor agonist, WAY-267,464, alleviates novelty-induced hypophagia 
in mice: Insights into changes in c-Fos immunoreactivity. Pharmacology 
Biochemistry and Behavior, 124, 367-372. doi:10.1016/j.pbb.2014.07.007 
Ramirez, K., Shea, D. T., Mckim, D. B., Reader, B. F., & Sheridan, J. F. (2015). 
Imipramine attenuates neuroinflammatory signaling and reverses stress-induced 
social avoidance. Brain, Behavior, and Immunity, 46, 212-220. 
doi:10.1016/j.bbi.2015.01.016 
 
 
84 
 
Ramirez, K., & Sheridan, J. F. (2016). Antidepressant imipramine diminishes stress-
induced inflammation in the periphery and central nervous system and related 
anxiety- and depressive- like behaviors. Brain, Behavior, and Immunity, 57, 293-
303. doi:10.1016/j.bbi.2016.05.008 
Reyes-Lagos, J. J., Hadamitzky, M., Peña-Castillo, M. Á, Echeverría, J. C., Bösche, K., 
Lückemann, L., . . . Pacheco-López, G. (2016). Exogenous oxytocin reduces signs 
of sickness behavior and modifies heart rate fluctuations of endotoxemic rats. 
Physiology & Behavior, 165, 223-230. doi:10.1016/j.physbeh.2016.07.013 
Ring, R. H., Malberg, J. E., Potestio, L., Ping, J., Boikess, S., Luo, B., . . . Rosenzweig-
Lipson, S. (2006). Anxiolytic-like activity of oxytocin in male mice: Behavioral 
and autonomic evidence, therapeutic implications. Psychopharmacology, 185(2), 
218-225. doi:10.1007/s00213-005-0293-z 
Ross, K. M., Mcdonald-Jones, G., & Miller, G. E. (2013). Oxytocin does not attenuate 
the ex vivo production of inflammatory cytokines by lipopolysaccharide-activated 
monocytes and macrophages from healthy male and female donors. 
Neuroimmunomodulation, 20(5), 285-293. doi:10.1159/000351610 
Ross, H. E., & Young, L. J. (2009). Oxytocin and the neural mechanisms regulating 
social cognition and affiliative behavior. Frontiers in Neuroendocrinology, 30(4), 
534-547. doi:10.1016/j.yfrne.2009.05.004 
Wang, P., Yang, H., Tian, S., Wang, L., Wang, S. C., Zhang, F., & Wang, Y. (2015). 
Oxytocin-secreting system: A major part of the neuroendocrine center regulating 
immunologic activity. Journal of Neuroimmunology, 289, 152-161. 
doi:10.1016/j.jneuroim.2015.11.001 
Yuan, L., Liu, S., Bai, X., Gao, Y., Liu, G., Wang, X., . . . Wang, Z. (2016). Oxytocin 
inhibits lipopolysaccharide-induced inflammation in microglial cells and 
attenuates microglial activation in lipopolysaccharide-treated mice. Journal of 
Neuroinflammation, 13(1). doi:10.1186/s12974-016-0541-7 
 
 
 
85 
 
Appendices 
Appendix A – Luminex Mouse Cytokine/ Chemokine Magnetic Bead Panel Kit Manual 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
Julie M. Deleemans 
Education 
Master of Science in Psychology     2014 – 2016 
Western University, London, ON. 
 Specialized in behavioural and cognitive neuroscience 
 Thesis Title: Oxytocin’s effects on sickness behaviours, anxiety 
responses, and immune function in adult male mice 
o Supervisors: Dr. Martin Kavaliers, Dr. Christine Tenk, & Dr. Klaus-
Peter Ossenkopp 
Bachelor of Arts - Honors Specialization in Psychology  2011 – 2014 
Brescia University College, London, ON 
 Specialized in developmental and health psychology 
 Thesis Title: The effects of neonatal LPS exposure on depressive-like 
behaviours in male and female adolescent rats 
o Supervisor: Dr. Christine Tenk 
Certificate in Human Services      2007 – 2008  
Fanshawe College, London, ON 
 Deans honor roll (2008)  
Academic & Teaching Experience  
Teaching Assistant        2014 – 2016  
Western University, London, ON 
 Psychology 1000 – Introduction to Psychology 
 
Teaching Assistant       2014 – 2016 
Brescia University College, London, ON 
 Psychology 2054 A/B – The Psychology of Eating 
Undergraduate Honors Thesis Student Co-Supervisor  2014 – 2016 
Western University, London, ON 
 Provided guidance and assistance with experimental procedures, data 
collection, analysis, and writing of thesis 
 
 
 
 
87 
 
Publications 
 
 Deleemans, J. M., Wang, K., Ossenkopp, K. P., Kavaliers, M., & Tenk, C. 
M. (2016). Effects of an oxytocin agonist and antagonist on 
lipopolysaccharide elicited locomotor, anxiety, and immune responses in 
male mice. Manuscript in preparation, Western Ontario University. 
 
 Deleemans, J. M., Ossenkopp, K. P., Tenk, C. M., & Kavaliers, M. (2015). 
Effects of the oxytocin agonist, carbetocin, on sickness behaviours and 
immune responses in male mice. Society For Social Neuroscience 
Abstracts.  
 
 Deleemans, J. M., Ossenkopp, K. P., Tenk, C. M., & Kavaliers, M. (2015). 
Effects of the oxytocin agonist, carbetocin, on sickness behaviours and 
immune responses in male mice. Society For Neuroscience Abstracts. 
(No. 811.02) 
 
 Deleemans, J. M., Ossenkopp, K.P., Tenk, C. M., & Kavaliers, M. (2015). 
The effects of oxytocin on sickness behaviours and anxiety responses in 
male mice. Southern Ontario Neuroscience Association Abstracts. 
Poster Presentations 
 Deleemans, J. M., Ossenkopp, K. P., Tenk, C. M., & Kavaliers, M. (2015). 
Effects of the oxytocin agonist, carbetocin, on sickness behaviours and 
immune responses in male mice. Presented at the Society For 
Neuroscience Meeting (Chicago, Illinois). 
 
 Deleemans, J. M., Ossenkopp, K. P., Tenk, C. M., & Kavaliers, M. (2015). 
Effects of the oxytocin agonist, carbetocin, on sickness behaviours and 
immune responses in male mice. Presented at the Society For Social 
Neuroscience Meeting, (Chicago, Illinois).  
 
 Deleemans, J. M., Ossenkopp, K.P., Tenk, C. M., & Kavaliers, M. (2015). 
The effects of oxytocin on sickness behaviours and anxiety responses in 
male mice. Presented at the Southern Ontario Neuroscience Association 
Meeting (Hamilton, Ontario). 
 
 
 
 
 
88 
 
 Deleemans, J. M., & Tenk, C. M. (2014). The effects of neonatal LPS 
exposure on depressive-like behaviours in male and female adolescent 
rats. Presented at the Brescia University College Psychology Honors 
Program Conference (London, Ontario). 
 
 K. Colasanti, J.M. Deleemans, K.P. Ossenkopp, & M. Kavaliers (2016). 
Effects of adolescent corticosterone treatment on anxiety-like behaviours 
in male rats. Presented at the Western University Psychology Honors 
Program Conference (London, Ontario).  
 
 K.M. Kezele, J.M. Deleemans, K.P. Ossenkopp, & M. Kavaliers (2015). 
Sexually dimorphic effects of neonatal LPS on anxiety-like behaviour in 
the dark-light paradigm following administration of a second acute adult 
immune challenge. Presented at the Western University Psychology 
Honors Programs Conference (London, Ontario). 
Related Experience 
Graduate Course - Animal Models in Behavioural Neuroscience 2015 
Western University, London, ON 
 Major Research Paper: Novel approaches to behavioural testing and 
naturopathic pharmacological treatments for depression 
 Research Project: Probiotic intervention in nutritionally deficient diet 
induced developmental models of mental illness 
 Conducted literature reviews for research studies, subsequent writing of 
research proposals, and developed protocols for project implementation 
 
Graduate Course - Research Design and Statistical Modeling 2014 – 2015  
Western University, London, ON 
 Univariate and multivariate statistical and modeling procedures 
 I. Foundational Statistics: sampling distributions, inferential statistics, 
confidence intervals, effect size, and power  
 II. ANOVA, ANCOVA and MANOVA: experimental and quasi experimental 
designs  
 III. Multiple Regression and Extensions: mediation, moderation, multilevel 
modeling, and models for categorical outcomes such as logistic regression 
 IV. Factor Analysis and Structural Equation Modeling 
 
 
 
 
 
89 
 
Summer Research Assistant         2014 
Western University, Kavaliers/Ossenkopp Lab 
 Conditioned place preference study with LPS and scopolamine – data 
collection, analysis, and report writing 
Professional Certifications 
 Western University Animal Care and Veterinary Services  2013 
o WebCT Animal Care and Use Course     
o Basic Rat and Basic Mouse Training 
o Injections and Blood Collection Techniques Training 
o Supported by the Canadian Council on Animal Care 
 Western University Basic WHMIS Training    2014 
 Western University Accessibility at Western (AODA)   2014 
o Accessibility in Teaching 
 Western University General Laboratory Safety and    2014 
Hazardous Waste Management Training 
 Western University Safe Campus Community     2014 
o Preventing Harassment, Violence and Domestic Violence 
 Western University Worker Health and Safety Awareness  2014 
Honors & Awards 
 Brescia University College Entrance Scholarship               2011 
 Brescia University College Deans honor roll    2012 – 2014 
 Western Graduate Research Scholarship    2014 – 2016 
Volunteer Experience 
 Editor – Western Undergraduate Psychology Journal  2014 – 2016  
 Nutrition/recipe contributor  
o InHealth Technologies Speakers Club newsletter     2016 
 Big Brothers Big Sisters mentoring program      2015 – 2016  
 Canadian Cancer Society       2009 – 2010  
Affiliations 
 Canadian Association of Psychosocial Oncology    2016 
 Society for Neuroscience       2015 – 2016  
 Society for Social Neuroscience     2015 – 2016 
 
